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Abstract 
 
Congeneric set of thirty-eight 4-aryl-4-oxo-2-(N-aryl/cycloalkyl)butanamides has been designed, 
synthesized and evaluated for acetyl- and butyrylcholinesterase inhibitory activity. Structural 
variations included cycloalkylamino group attached to C2 position of butanoyl moiety, and 
variation of amido moiety of molecules. Twelve compounds, mostly piperidino and imidazolo 
derivatives, inhibited AChE in low micromolar range, and were inactive toward BChE. Several 
N-methylpiperazino derivatives showed inhibition of BChE in low micromolar or submicromolar 
concentrations, and were inactive toward AChE. Therefore, the nature of the cycloalkylamino 
moiety governs the AChE/BChE selectivity profile of compounds. The most active AChE 
inhibitor showed mixed-type inhibition modality, indicating its binding to free enzyme and to 
enzyme-substrate complex. Thorough docking calculations of the seven most potent AChE 
inhibitors from the set showed that the hydrogen bond can be formed between amide -NH- 
moiety of compounds and -OH group of Tyr 124. The 10 ns unconstrained molecular dynamic 
simulation of the AChE-compound 18 complex shows that this interaction is the most persistent. 
This is, probably, the major anchoring point for the binding. 
 
Keywords: 4-Aryl-4-oxo-2-aminylbutyramides; Anticholinesterase activity; Mixed type 
reversible inhibitors; Docking study; Molecular dynamics 
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1. Introduction 
 
Acetylcholinesterase (AChE) is a carboxylesterase which terminates cholinergic neuro-
transmission, by hydrolyzing neurotransmitter acetylcholine (ACh) in a synaptic cleft. Reversible 
AChE inhibition is implicated in a number of disorders, including Alzheimers disease (AD) [1], 
Myasthenia gravis [2], glaucoma [3], and can be used as a pretreatment against nerve agents’ 
intoxications [4,5]. Recently, AChE’s sister enzyme butyrylcholinesterase, also became 
important as pharmacological target for AD. BChE is capable to compensate AChE catalytic 
functions in synaptic cleft [6,7] and its activity significantly rises during time course in AD [8,9]. 
Therefore, in designing and testing of reversible inhibitors it is advisable to monitor activity 
toward both enzymes. 
 
AChE contains 20 Å deep and narrow gorge, in which five regions that are involved in the 
substrate, irreversible and reversible inhibitor binding, can be distinguished (human and electric 
eel AChE numbering): (1) catalytic triad residues: Ser 203, His 447, and Glu 334, [10] at the 
bottom of the gorge, which directly participate in catalytic cycle, by charge relay mechanism, as 
in other serine esterases; (2) oxyanion hole: is an arrangement of hydrogen bond donors which 
stabilize the transient tetrahedral enzyme-substrate complex by accommodation of negatively 
charged carbonyl oxygen. This region inside the active center is formed by backbone -NH- 
groups of amino acid residues Gly 121, Gly 122 and Ala 204 [11,12]; (3) the ‘anionic site’(AS), 
where Trp 86 is situated. This residue is conserved in all cholinesterases and it is involved in 
orientation and stabilization of trimethylammonium group of AChE, by forming cation-π 
interactions [13-16]; (4) acyl pocket comprises two phenylalanine residues, 295 and 297, which 
interact with the substrate acyl group. They form the clamps around methyl group, and decrease 
its degrees of freedom [17]; (5) peripheral anionic site (PAS) [18-20], comprises residues which 
are located at the rim of the active site gorge, Tyr 72, Tyr 124, Trp 286 and Asp 74. Possible 
binding sites for the reversible inhibitors comprise both AS and PAS. The so-called dimeric 
(dual) inhibitors bind simultaneously to both of these sites. In BChE active site, six out of 
fourteen aromatic amino acid residues in AChE (Tyr 72, Tyr 124, Trp 286, Phe 295, Phe 297 and 
Tyr 337) are replaced by aliphatic ones (Asn 68, Gln 119, Ala 277, Leu 286, Val 288, and Ala 
328). This causes 200 Å3 larger active site gorge of BChE, comparing to that of AChE. 
Therefore, BChE is capable to hydrolyze wide variety of esters [21].  
 
Recently, we reported congeneric series of the twenty 4-aryl-4-oxo-2-aminylbutanamides, 
with variation of substitutents on the aroyl phenyl ring, while phenylamido moiety was retained 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTunchanged [22]. Alkyl substituted congeners inhibited both AChE and BChE in micromolar 
concentrations, while chloro- or methoxy- substituted compounds were proved as inactive. The 
nature of cycloalkylamino moiety of molecules governed the AChE/BChE selectivity: piperidino 
and imidazolo derivatives were active toward AChE, while morpholino derivatives were active 
toward BChE.  
 
In the present work, we investigated the influence of the amido moiety variation on AChE 
and BChE inhibition potency and selectivity. We systematically changed the cyclic amine used 
to obtain precursor aroylacrylic acid amides (3,5-dimethoxyaniline, 4-isopropylaniline and 
cyclohexylamine), retaining the favorable alkyl substituents (4-i-Pr, 2,4-di-i-Pr and β-tetralinyl) 
on the aroyl part of the molecule. For the Michael addition on the activated double bond, four 
amines were used: piperidine, imidazole, morpholine and N-methylpiperazine. Along with this, 
two more compounds were synthesized. To test the effects of the presence of highly voluminous 
moiety at position C2 of the butanoic scaffold on the AChE and BChE inhibiton activity, we 
synthesized addition products of 4-benzylpiperidine on the 4-(4-i-Pr-Ph)-4-oxo-2-butenoic acid 
phenylamide, and of 4-(2-N,N-di-Me-aminoethyl)-1-piperazine on the 4-(4-i-Pr-Ph)-4-oxo-2-
butenoic acid 3,5-di-MeO-phenylamide. The last derivative comprises moiety that mimick 
trimethylaminoethyl group of the acetylcholine. Overall, thirty-eight compounds were prepared 
and their AChE and BChE inhibition activity determined. Possible interactions of the most 
potent derivatives with the AChE active site residues were further investigated by docking 
calculations and by molecular dynamics. 
 
2. Results and discussion 
 
2.1. Chemistry 
 
Synthetic path to 1-38 is given in Scheme 1. Friedel-Crafts acylation of the commercially 
available substituted benzenes (A) with maleic acid anhydride (B) yields aroylacrylic acids (C) 
[23]. Subsequently, acids were converted to acid chlorides in dry THF by phosphorous-
oxychloride, then in situ reacted with equimolar amounts of primary amine (3,5-
dimethoxyaniline, 4-isopropylaniline and cyclohexylamine) to give the corresponding amides 
(D) [24]. Michael addition of the cyclic amines (piperidine, imidazole, morpholine, N-
methylpiperazine, 4-benzylpiperidine and 4-(2-N,N-di-Me-aminoethyl)-1-piperazine proceeded 
smoothly to give target compounds 1-38.  
 
Please put Scheme 1 here  
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2.2. Structure-activity relationships 
 
Inhibition potency of the compounds 1-38 toward AChE and BChE, given as IC50 values, are 
shown in Table 1, along with potency data of the previously published congeners having 
unsubstituted phenylamido moiety (1a-9a) [22]. Due to limited solubility of some derivatives, 
we were unable to obtain entire dose-response curve (spanning range of 20-80% of the enzyme 
activity inhibition). For those compounds we reported the percent of the residual enzyme activity 
at the highest concentration tested. 
 
Please put Table 1 here 
 
Twelve compounds, out of twenty that inhibited AChE activity, were active in low micromolar 
concentrations. Most of the piperidino and imidazolo derivatives showed inhibition of AChE in 
low micromolar range, while morpholino and N-methylpiperazino derivatives were inactive up to 
concentrations of 15-20 µM. Clearly, the presence of bulkier substituents in position C2 of the 
butanoyl moiety of molecules reduces anti-AChE activity. Similar trend was also observed with 
previously synthesized compounds [22]. 
 
3,5-Dimethoxy substitution at phenylamido moiety of the imidazolo and piperidino 
derivatives, in some instances (compare 2 with 2a, and 26 with 8a) only slightly enhanced 
inhibition potency, while in others (compare 13 with 4a, 14 with 5a and 25 with 7a) only slightly 
diminished inhibition potency. 4-Isopropyl substituted phenylamido moiety in piperidino and 
imidazolo derivatives, in most cases (6, 17, 18, 30) slightly improved anti-AChE inhibition 
potency, comparing to the unsubstituted counterparts (2a, 4a, 5a and 8a). In some instances, 4-i-
Pr substitution had clearly beneficial influence on anti-AChE activity. This is especially evident 
in compounds 19 and 20, in which this type of substitution turns inactive morpholino and N-
methylpiperazino derivatives into active ones, with IC50 values around 6.5 µM.  
 
The change of the phenyl moiety to cyclohexyl on amido part of the piperidino and imidazolo 
derivatives (9, 10, 33, 34) reduced anti-AChE activity for at least one order of magnitude. This 
indicates that amido moiety of the molecules probably interacts with AChE active site residues 
involving π electrons of the phenyl ring. The decrease in inhibition potency, due to the presence 
of cyclohexyl moiety, was modest only for 2,4-di-i-Pr-substituted piperidino and imidazolo 
derivatives 21 and 22, with IC50 values of 5.44 and 5.94 µM, respectively.  
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Nineteen derivatives influenced BChE activity (expressed as residual enzyme activity at 
highest concentration tested, Table 1), but only three compounds had IC50 values in low 
micromolar (16 and 24), or submicromolar concentrations (20). All three compounds bear 2,4-di-
i-Pr-substituted aroyl and  N-methylpiperazino moieties. We expected that, due to a larger BChE 
active site gorge, bulkier substituents on phenylamido moiety will increase potency of 
compounds comparing to unsubstituted derivatives, described earlier. Surprisingly, 2,4-di-i-Pr  
morpholino derivatives (15 and 19) with 3,5-dimethoxy or 4-isopropyl substitutents on  
phenylamido moiety did not appear more potent, comparing to unsubstituted derivative 6a 
reported in previous work (IC50 = 2.48 µM). β-Tetralinyl substituted N-methylpiperazino 
derivatives 28, 32 and 36, appeared moderately potent, with IC50 values in the range of 10-20 
µM. All other compounds didn’t produce significant inhibition of BChE activity. 
 
To test the effects of the presence of highly voluminous moiety at position C2 of the butanoic 
moiety of molecules on the AChE and BChE inhibiton activity, we synthesized derivative 37, by 
the addition of 4-benzylpiperidine. We aimed to test whether this group will cause an increase in 
inhibiton potency and whether such compound has different mode of binding to enzyme active 
site (to PAS instead to AS), comparing to other derivatives. In compound 38, we introduced 
dimethylaminoethyl moiety, a group that mimick trimethylaminoethyl group of ACh. 
Unfortunately, both derivatives appeared inactive at the highest concentration tested (20 µM). 
 
The spectrophotometric method of Ellman was used to determine the type of inhibition and 
the Ki for derivative 17, most active toward AChE. Compound exhibited mixed type of 
inhibition. This behavior was indicated by intersection of double reciprocal lines in the upper left 
quadrant of Lineweaver-Burk plot, shown in Figure 1 and Table S1, Supplementary information. 
Generally, this type of inhibition indicates binding to free enzyme and enzyme-substrate 
complex; that is, a possible binding to the site distant from the active site. The Ki’s obtained were 
0.52 µM (binding to free enzyme) and 1.93 µM (binding to enzyme-substrate complex). 
 
Please put Figure 1 here  
 
2.3. Molecular modeling 
 
3D-QSAR model described in previous article [22] was used to predict potency of compounds 
for which we obtained IC50 values in this study. Fair predictivity was obtained for compounds 2, 
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was overestimated in some extent. Results are given in Table S2 in Supplementary Material.  
 
Along with this, we built independent 3D QSAR model by GRIND-2 descriptors for all 
compounds for which IC50 values toward AChE were obtained, reported in this, and in previous 
study [22]. In this model we also included compounds for which we obtained residual enzyme 
activity on defined concentration of the inhibitor (4, 9-12, 19, 20 and 32). For the later subset of 
compounds we estimated IC50 values. For model building all available GRID probes were used, 
DRY (hydrophobic), N1 (HBD), O (HBA) and TIP (shape probe). PLS coefficients plot for the 
model obtained with 3LV are shown in Figure 2. Although we didn’t included shape probe in the 
model reported in previous work, because this model contained structurally diverse set of 
compounds, and good results were obtained using hydrophobic, HBD and HBA probes; DRY-
DRY, N1-N1 and DRY-O blocks, common for both models, resemble each other. DRY-DRY 
block is filled with variables positively correlated with potency of compounds, implying positive 
contribution of hydrophobic moieties of compounds to activity. Although variables were 
expressed for all compounds in the set, higher intensity of variables for the most potent 
compounds in this block can be observed, comparing to least potent ones. This implies stronger 
hydrophobic interactions that most potent compounds can make with the respective biological 
target. Heatmaps of DRY-DRY block are depicted in Figure S3a in Supplementary Material. It 
should be noted that we also observed rough positive trend between potency of compounds and 
their apolar surface areas calculated from 3D structures (data not shown).  In N1-N1 block 
majority of variables are negatively correlated with potency of compounds. Heatmaps of N1-N1 
block also show higher intensity of variables associated with less potent compounds, comparing 
to more potent ones, Figure S3b in Supplementary Material. Variable O-TIP 473 (10.0-10.4 Å), 
has the highest positive impact on the overall model. It is expressed for the most active 
derivatives and connects MIF’s of HBA probe (O), associated with amido -NH- group, and 
MIF’s of  shape (TIP) probe associated with substituents on the phenylamido ring (4-i-Pr or 3,5-
di-OMe, Figure S4 and Table S5, Supplementary Material). For compounds with unsubstituted 
phenylamido moiety TIP node is associated with substituents on aroyl phenyl ring. The 5LV 
PCA model explains about 55 % variability in the set (Table S6, Supplementary Material). 
Statistics of the model is shown in Table 2. Reported r2 and q2 values were obtained after one 
cycle of the variable selection by fractional factorial design.  Experimental and calculated p(IC50) 
values, obtained with 3 LV, are shown in Table S5 in Supplementary Material.  
Please put Figure 2 here 
Please put Table 2 here 
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µM were docked into the AChE active site. Both enantiomers of the each compound were 
docked in mAChE (Mus musculus, PDB entry 2HA2), using the latest version of AutoDock 4 
package [25]. Fifty binding poses were generated in each docking calculation. As the scoring 
functions used for prioritization of the obtained poses are still mostly inaccurate, [26], we 
decided to analyse the most favorable binding pose (according to the estimated free energy of 
binding, ∆G) along with the best pose, belonging to the most populated cluster, by LigPLot 
program [27]. Detailed data with the list of all ligand-AChE interactions are given in Table 3. It 
should be noted that in both types of docking poses (best ranked pose and the most populated 
one), for all compounds shown in the Table 3, the hydrogen bond between amide -NH- group of 
the compounds and -OH group of Tyr 124 side chain is formed. Also, in significant number of 
poses, a hydrogen bond between Phe 295 backbone -NH- group and different moieties of ligands 
(phenylamido -OCH3 group, N3 nitrogen of imidazole ring, or aroyl carbonyl group) is formed. 
The residues which form hydrophobic interactions with docked compounds, in majority of poses, 
are His 447, Tyr 341, Phe 295, Phe 297 and Phe 338.  
 
Please put Table 3 here 
 
The overall description of the docking poses for all compounds is beyond the scope of this 
article. In the following lines we will provide detailed discussion of the obtained docking 
solutions for the three most potent derivatives, 6, 17 and 18, shown in the Figure 3. The S 
enantiomers are colored cyan and the R are colored red. Surprisingly, we found that R and S 
enantiomers of the each compound were docked in a mutually very similar fashion. The RMSD 
differences between atomic positions of docked poses of two enantiomers were less than 2.077 Å 
(heavy atom superposition), Table S7 in Supplementary Material. In the Figure 3a and 3b the 
docking solutions best ranked by the estimated free energy of binding (∆G), for the compounds 
17 and 18, are shown. Both enantiomers of both compounds are oriented within the AChE active 
site gorge in the similar fashion. The aroyl moieties are oriented toward the bottom of the gorge, 
interacting with Trp 86 and Tyr 337 residues. Amido -NH- groups of the compounds form 
hydrogen bond with the side chain -OH group of Tyr 124. Phenylamido rings of both compounds 
are directed toward the entrance of the gorge (PAS) and interact with side chains of Trp 286, Phe 
295 and Phe 297. The piperidine ring of compound 17 and the imidazole ring of compound 18 
are found in the close proximity of catalytic triad residues, His 447 and Ser 203. Nitrogen N3 of 
the imidazole ring of both enantiomers of compound 18 forms hydrogen bond with side chain 
oxygen of Ser 203. Aroyl phenyl ring and the corresponding cycloalkylamino groups are also 
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best docking poses, that belong to the most populated cluster, for the compounds 17 and 18 are 
shown. The orientation of the ligands is reversed, comparing to the energetically favored poses 
(Fig 3a and 3b). Aroyl moieties of the ligands are accommodated at the entrance of the gorge 
(PAS), interacting with aromatic side chains of Trp 286 and Tyr 72. Phenylamido rings of the 
both compounds are directed toward the bottom of the AChE active site gorge and interact with 
the side chains of Tyr 337, Phe 338 and Trp 86 residues. The hydrogen bond between amido -
NH- group and the side chain -OH of Tyr 124 is retained. The important difference between 
energetically favorable and the most populated docking poses for compounds 17 and 18 lies in 
the fact that ligands are found closer to the entrance of the gorge in the poses which belong to the 
most populated cluster. The upper part of the AChE active site gorge is wider, and can easily 
accommodate voluminous diisopropyl-substituted aroyl groups of 17 and 18, in a variety of 
slightly different, but essentially similar conformations. Most probably because of this, the 
search algorithm was able to find more similar poses belonging to the same cluster. One 
important consequence of this is that cycloalkyl amino moieties of 17 and 18 are found near acyl 
pocket residues Phe 295 and Phe 297, instead near catalytic triad residues His 447 and Ser 203, 
as observed in the best ranked docking pose; therefore, in the most populated pose of 18, N3 
nitrogen of the imidazole ring forms hydrogen bond with backbone -NH- group of Phe 295. 
However, in both classes of poses, the hydrogen bond between amido -NH- group and side chain 
-OH group of Tyr 124 existed.   
 
Docking poses of the both enantiomers of compound 6 are shown in Fig. 3e. Cluster which 
comprised the best ranked pose (according to the estimated ∆G of binding) was also the most 
populated one. Both enantiomers were docked almost identically into the AChE active site 
gorge, and established the same type of interactions with amino acid side chains of the enzyme 
(see Table 2.). The estimated free energies of binding for the both enantiomers appeared very 
similar, –11.15 and –11.11 kcal/mol, for S and R, respectively. Phenylamide rings of both 
enantiomers are directed toward the bottom of the AChE active site gorge, and form hydrophobic 
interactions with aromatic side chains of Phe 338, Tyr 337 and Trp 86. The aroyl phenyl rings of 
the both R and S enantiomers are directed toward the entrance of the gorge, and interact with Tyr 
72, Asp 74 and Trp 286 (residues that belong to PAS). Oxygen of the aroyl carbonyl group forms 
hydrogen bond with the backbone -NH- group of Phe 295. For this compound, only few poses 
(out of 50) were found with the aroyl phenyl ring directed toward bottom of the gorge, but with 
considerably lower estimated free energy of binding. So, when there are no voluminous 2,4-
diisopropyl groups at aroyl moiety, which can establish important hydrophobic contact with the 
amino acid residues in the active site of AChE, and give rise to the energetically most favored 
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pose becomes also the energetically favored one, with phenylamido moiety directed toward 
bottom of the gorge, and aroyl phenyl ring directed toward the entrance of the gorge.  
 
Please put Figure 3 here 
 
The docking studies provided valuable insight into possible interactions between the three 
most active derivatives (6, 17 and 18) and AChE active site residues. From exhaustive analysis 
of the docking poses it can be shown that there are two possible orientations of the ligands within 
the AChE active site gorge. One with aroyl moiety directed toward the bottom of the gorge, and 
the other with aroyl moiety directed toward the entrance of the gorge. The later one, in most of 
the solutions, belonged to the most populated cluster of conformations. Majority of the 
derivatives, in both classes of docking poses showed hydrogen bonding with Tyr 124 residue.  
 
Protein flexibility was not accounted in our docking study.  The knowledge on the non-
covalent contacts between enzyme and ligand over time may provide additional information 
about most persistent interactions and the stability of the protein-ligand complexes. We 
performed the unconstrained, 10 ns molecular dynamics simulation, starting from the most 
populated docking pose of the S enantiomer of compound 18. The movie, obtained from 
trajectory is given as Supplementary Material. The most important distances between AChE 
active site residues and the ligand obtained from simulation are shown in Figure 4. During the 
simulation, ligand moves toward the entrance of the gorge, as can be seen by a gradual increase 
of the distance between the centroid defined on the indole ring of Trp 86 and the phenylamido 
ring of compound 18 (4 to ~ 12 Å, Fig. 4a). After 5 ns, this distance remains stable until the end 
of the simulation. We also monitored the distance between aroyl ring of compound 18 and Trp 
286 side chain (PAS residue). A major fluctuation of the distance between centroids defined on 
Trp 286 indole ring and aroyl phenyl moiety is observed during the first ns of the simulation 
(from 4.5 to almost 11 Å, Fig 4b, blue squares). After this time, fluctuation of the distance 
appeared stable, with an average value of 7.5 Å. After 5 ns of simulation, the ligand rotates 
around the axis which passes through centroids defined on the aroyl and on the phenylamido 
rings, so the distance gradually increases. We also monitored the distance between methyl group 
of ortho-i-Pr moiety and centroid defined on the indole ring of Trp 286. The profile of this 
distance (Figure 4b, violet dots) is similar to aroyl-Trp 286 distance, and suggests a stable 
CH···π interaction with an average distance of 4 Å, from 1st to 5th ns of the trajectory. As a result 
of ligand rotation, this distance gradually increases from 5th ns to 8th ns, and after this time, 
remains stable with average value of 12 Å. Docking calculations suggested a hydrogen bond 
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of compound 18. We monitored this distance during simulation (Fig. 4c, green dots). This 
hydrogen bond appeared persistent only at the very beginning of the simulation, in the first 500 
ps. From 1 ns to 4 ns of the simulation, the distance gradually increases. After 4 ns, the hydrogen 
bond between these two groups is formed again, and remains stable to the end of 5th ns. After 
this time, the bond breaks, as a result of ligand rotation. As a consequence of ligand rotation, 
imidazole ring is directed toward Tyr 124, and hydrogen bond is formed between the N3 of 
imidazole ring and the -OH group of Tyr 124 (Fig. 4c, red dots). The existence of this hydrogen 
bond is also evident from 500th ps to the end of 1st ns of the MD trajectory, the same time 
interval in which hydrogen bond of imidazole ring N3 and backbone -NH- group of Phe 295 
cannot be observed. The distance between the side chain -OH oxygen atom of Tyr 124 and the 
amido -NH- of compound 18 is shown in Fig 4d. This H-bond remains stable throughout the 
whole 10 ns of MD simulation. Only temporary increase of this distance appeared around the 3rd, 
6th and 8th ns of the simulation. Beyond that, the hydrogen bond is stable, with overall occupancy 
of 62.02 %. One additional hydrogen bond was observed, between -OH group of Tyr 72 and 
carbonyl group of the ligand, from the 7th ns till the end of the simulation, (Fig 4e). According to 
the results of this MD simulation, the most persistent, and therefore, probably, the most 
important interactions between compound 18 and the AChE active site residues involve 
following hydrogen bonds: persistent H-bond between Tyr 124 -OH group and amido -NH- 
moiety of the ligand; a fine interplay of hydrogen bonds between imidazole N3 atom of the 
compound  and the Tyr 124-OH group, or the backbone -NH- group of Phe 295; as well as the 
hydrogen bond between aroyl carbonyl group of compound  and the Tyr 72 -OH group. Since the 
ligand moves slightly toward the entrance of the gorge, and therefore lose interactions with Trp 
86 residue, we suppose that additional, more voluminous substituents in para-position of 
phenylamido moiety will increase the inhibition potency of compounds. 
 
Please put Figure 4 here 
 
To explore possible binding modes for the compounds active toward BChE, and to reveal 
possible reasons for the selectivity of compounds toward one or another enzyme, we docked both 
enantiomers of compounds 16 and 20 into BChE active site (PDB entry 1P0I). The results are 
shown in the Figure 5, S enantiomers are colored cyan and R are colored red. The ligands occupy 
the same spatial region of the active site, and interact with BChE amino acid residues primarily 
through hydrophobic interactions. The S and R enantiomers of compound 16 have slightly 
different modes of binding (Fig 5a). Aroyl phenyl ring of the S isomer of compound 16 is 
pointed toward the catalytic triad residues, His 438 and Ser 198. Aroyl carbonyl group forms 
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enzyme, and forms close contact with Asn 83, while the amide bond of S enantiomer of 
compound 16 is found near Trp 82. The N-methyl group on the piperazine ring forms CH···π 
interaction with Trp 430 side chain. The orientation of the R enantiomer of compound 16 
appeared slightly different. Aroyl phenyl ring is situated near Trp 82 residue. The N-
methylpiperazine ring is pointed toward the entrance of the gorge and does not make any 
important interactions. The 3,5-dimetoxy substituted phenylamido ring is found near the Thr 
120.  
Both enantiomers of compound 20 have similar binding modes inside BChE active site (Fig. 
5b). Phenylamido rings are found near catalytic triad residues His 438 and Ser 198. N-
methylpiperazino ring makes van der Waals interactions with Tyr 332 residue. Aroyl ring is 
situated in the anionic site of the enzyme, and forms hydrophobic interactions with Trp 82. The 
ortho-i-Pr group of aroyl ring forms close contacts with Gly 115, Gly 116 and Gly 117 
(oxyanion hole residues). Any hydrogen bonding between enantiomers of compound 20 and the 
amino acid residues of BChE was not observed. 
 
Please put Figure 5 here 
 
The binding modes of compounds 6, 17 and 18 in the AChE active site are significantly 
different from the binding modes of compounds 16 and 20 in the BChE active site. As is 
mentioned in the introduction, six out of fourteen aromatic amino acid residues in AChE (Tyr 72, 
Tyr 124, Trp 286, Phe 295, Phe 297 and Tyr 337) are replaced by aliphatic ones (Asn 68, Gln 
119, Ala 277, Leu 286, Val 288, and Ala 328) in BChE. This causes 200 Å3 larger active site 
gorge of BChE, comparing to that of AChE. Most probably because of this, compounds 16 and 
17 are deeply buried inside of BChE active side gorge, and oriented in way that two rings of the 
molecules are situated in the bottom of the gorge, one usually directed toward Trp 82 (anionic 
site) and the other toward Ser 198 and His 438 (catalytic triad residues). In contrast to this, 
compounds 6, 17 and 18 are oriented in a way that one aromatic ring interacts with AS and the 
other one with PAS of AChE, with smaller cycloalkylamino moiety accommodated in the middle 
of the gorge. This binding mode is probably a consequence of the less voluminous AChE active 
site gorge comparing to BChE’s. It is very probable that due to bulkiness of N-methylpiperazine 
ring (comparing to imidazole and piperidine ring), compounds 16 and 20 cannot be 
accommodated inside AChE active site, and therefore these compounds selectively inhibit 
BChE. Along with this, interactions of compounds 16 and 20 with BChE are primarily 
hydrophobic by nature (only one hydrogen bond is observed for compound 16), while compound 
18 establish few important hydrogen bonds with the Tyr 72 and the Tyr 124 residues of AChE; 
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Gln 119 in BChE. Therefore the architecture of the BChE active site is slightly different, 
comparing to AChE, and those residues cannot play the same role of hydrogen bond 
donors/acceptors as corresponding residues in AChE. Moreover, compounds 6, 17, 18 are less 
voluminous comparing to 16 and 20, and probably cannot establish necessary hydrophobic 
contact in sufficient extent for the effective binding to the wider BChE active site gorge. 
 
3. Conclusions 
 
In continuation of our work, we further investigated influence of structural modifications of 4-
aryl-4-oxo-2-aminylbutyramides on AChE and BChE inhibiton activity. We explored the 
influence of the amido part of molecules on the AChE/BChE inhibition activity and selectivity, 
changing the amido moiety from phenyl to 3,5-dimethoxyphenyl, 4-isopropylphenyl and 
cyclohexyl and keeping the favorable alkyl substituents (2,4-di-isopropyl, 4-isopropyl and β-
tetralinyl) on the aroyl part of the molecules. For the Michael addition to the activated double 
bond, piperidine, imidazole, morpholine, N-methylpiperazine, 4-benzylpiperidine and 4-(2-N,N-
di-Me-aminoethyl)-1-piperazine were used. Twelve compounds, mostly piperidino and 
imidazolo derivatives, inhibited AChE in low micromolar range, and were inactive toward 
BChE. Three compounds inhibited BChE in low micromolar or submicromolar concentrations. 
All three compounds bear 2,4-diisopropyl substituted aroyl moiety and a N-methylpiperazine 
ring at position C2 of butanoic part of molecule. As with previous set of compounds, the nature 
of cycloalkylamino moiety governed the AChE/BChE selectivity of the compounds. The most 
active AChE inhibitor, compound 17, exhibited mixed type reversible inhibition, indicating its 
binding to free enzyme and enzyme-substrate complex. The docking study, performed with the 
seven derivatives having IC50 values below 5 µM, showed that for all compounds a hydrogen 
bond between amido -NH- group of compounds and Tyr 124 -OH group can be formed. The 
unconstrained, 10 ns molecular dynamics simulation of the complex between AChE and 
compound 18, showed that most persistent ligand-protein interaction is hydrogen bond between 
Tyr 124 -OH group and amido -NH- moiety of compound. Few additional hydrogen bonds were 
also found. Although moderately active, reported compounds will be used as templates for 
further structural modifications, in order to find structural requirements needed for higher 
potency. 
  
4. Experimental 
 
4.1. Chemistry 
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All chemicals were purchased from Sigma-Aldrich or Merck, and were used as received. Dry 
CH2Cl2 was used for Friedel-Crafts acylations. Melting points were determined in open capillary 
tubes on SMP-10 Stuart apparatus, and are uncorrected. 1H and 13C NMR spectra were recorded 
in CDCl3 on Varian Gemini 200/50 MHz or Bruker AVANCE 500/125 MHz instruments. NMR 
spectra of representative compounds are shown in Figure S7, Supplementary Material. Chemical 
shifts are reported in parts per million (ppm) relative to tetramethylsilane (TMS) as internal 
standard. Spin multiplicities are given as follows: s (singlet), d (doublet), t (triplet), m 
(multiplet), or br (broad). The HR ESI-MS spectra were recorded on Agilent Technologies 6210-
1210 TOF-LC-ESI-MS instrument in positive mode. Samples were dissolved in MeOH. All 
compounds prove > 98% purity, as obtained by instrumental methods of analysis.  
 
4.2. Characterization of the compounds 1-38 
 
4.2.1. N-(3,5-Dimethoxyphenyl)-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-(1-piperidinyl)butanamide 
(1). 
C26H34N2O4, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (3,5-dimethoxy-
phenyl)amide (0.85 mmol) and a corresponding amount of piperidine, 0.179 g of 1 was obtained, 
48.05% yield, light yellow solid, m.p. = 111-113 ºC, (toluene). 1H NMR (200 MHz, CDCl3) δ: 
1.28 (d, 6H, J=7.59 Hz, i-PrCH3); 1.47 (m, 2H, piperidinyl -CH2-); 1.63 (m, 4H, piperidinyl -
CH2-); 2.57 (t-like, 4H, J=5.16 Hz, piperidinyl -CH2-); 2.93-3.04 (overlapped m, 2H, i-PrCH and 
ABX); 3.66 (dd, 1H, J1,2=6.37 Hz, J1,3=9.40 Hz, ABX); 3.77 (s, 6H, -OCH3); 4.26 (dd, 1H, 
J1,2=5.16 Hz, J1,3=9.41 Hz, ABX); 6.22 (t-like, 1H, J1,2 =4.25 Hz, amido-p-phenyl); 6.79 (s, 1H, 
amido-o-phenyl); 6.80 (s, 1H, amido-o-phenyl); 7.33 (d, 2H, J=8.50 Hz, aroyl-m-phenyl); 7.97 
(d, 2H, J=8.50 Hz, aroyl-o-phenyl); 9.47 (s, 1H, amido -NH-). 13C NMR (50 MHz, CDCl3) δ: 
22.38; 22.58; 23.60; 23.87; 26.71; 31.85; 34.16; 44.48; 51.00; 55.35; 96.32; 97.36; 126.65; 
128.51; 134.81; 139.61; 154.54; 161.04; 170.60; 198.22. ESI-MS HR: 439.2587 (M +1), Calc. 
439.2597. 
4.2.2. N-(3,5-Dimethoxyphenyl)-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-(1-imidazolyl)butanamide 
(2).  
C24H27N3O4, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (3,5-dimethoxy-
phenyl)amide (0.85 mmol) and a corresponding amount of imidazole, 0.249 g of 2 was obtained, 
69.55 %  white solid, m.p. = 150-151 ºC (toluene). 1H NMR (200 MHz, CDCl3) δ: 1.24 (d, 6H, 
J=6.71 Hz, i-PrCH3); 2.93 (m, 1H, J1,2=7.05 Hz, J1,3=14.11 Hz, i-Pr-CH); 3.50 (dd, 1H, J1,2=5.64 
Hz, J1,3=18.11 Hz, ABX); 3.66 (s, 6H, -OCH3); 4.08 (dd, 1H, J1,2=7.29 Hz, J1,3=18.11 Hz, 
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(s, 1H, amido-o-phenyl); 6.82 (s, 1H, amido-o-phenyl); 7.16 (s, 1H, imidazolyl-CH-); 7.21 (s, 
1H, imidazolyl-CH-); 7.26 (d, 2H, J=8.00 Hz aroyl-m-phenyl); 7.64 (s, 1H, imidazolyl-CH-); 
7.84 (d, 2H, J=7.86, Hz aroyl-o-phenyl); 10.30 (s, 1H, amido -NH-). 13C NMR (50 MHz, CDCl3) 
δ: 23.49; 34.20; 41.73; 55.19; 56.75; 97.17; 98.12; 118.04; 126.83; 128.42; 129.44; 133.57; 
137.41; 139.70; 155.60; 160.86; 166.56; 195.84. ESI-MS HR: 422.2074 (M +1), Calc. 422.2080. 
4.2.3. N-(3,5-Dimethoxyphenyl)-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-(4-morpholinyl)butan-
amide (3). 
C25H32N2O5, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (3,5-dimethoxy-
phenyl)amide (0.82 mmol) and a corresponding amount of morpholine, 0.275 g of 3 was 
obtained, 76.01 % yield, light yellow solid, m.p. = 155-157 ºC (toluene). 1H NMR (200 MHz, 
CDCl3) δ: 1.27 (d, 6H, J=7.46 Hz, i-PrCH3); 2.64 (t-like, 4H,  J1,2=4.00 Hz, morpholino-CH2-); 
2.90-3.04 (overlapped m, 2H, i-PrCH and ABX); 3.64-3.86 (overlapped m, 11H, morpholino-
CH2-, ABX and -OCH3); 4.27 (dd, 1H, J1,2=5.14 Hz, J1,3=7.14 Hz, ABX); 6.23 (t like, 1H, J1,2 
=2.82 Hz, amido-p-phenyl); 6.78 (s, 1H, amido-o-phenyl); 6.79 (s, 1H, amido-o-phenyl); 7.33 (d, 
2H, J=8.46 Hz, aroyl-m-phenyl); 7.96 (d, 2H, J=7.81 Hz, aroyl-o-phenyl); 9.22 (s, 1H, amido–
NH-). 13C NMR (50 MHz, CDCl3) δ: 23.54; 32.10; 34.14; 49.96; 55.30; 65.02; 67.30; 96.45; 
97.46; 129.69; 128.45; 134.59; 139.34; 157.74; 161.04; 169.73; 197.74. ESI-MS HR: 441.2389 
(M +1), Calc. 441.2389. 
 
4.2.4. N-(3,5-Dimethoxyphenyl)-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-[1-(4-methylpiperazinyl)]-
butanamide (4). 
C26H35N3O4, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (3,5-dimethoxy-
phenyl)amide (0.82 mmol) and a corresponding amount of 4-methylpiperazine, 0.159 g of 4 was 
obtained, 42.68 % yield, white solid, m.p. = 120-122 ºC (toluene). 1H NMR (200 MHz, CDCl3) 
δ: 1.27 (d, 6H, J=7.36 Hz, i-PrCH3); 2.32 (s, 3H, N-CH3); 2.52 (br, 4H, piperazine-CH2-); 2.67 
(br, 4H, piperazine-CH2-); 2.93-3.08 (overlapped m, 2H, ABX and i-PrCH3); 3.63-3.77 
(overlapped signals, 7H, ABX and -OCH3); 4.34 (dd, 1H, J1,2=5.10 Hz, J1,3=6.86 Hz, ABX); 
6.23 (br, 1H, amido-p-phenyl); 6.79 (s, 1H, amido-o-phenyl); 6.80 (s, 1H, amido-o-phenyl); 7.32 
(d, 2H, J=8.43, aroyl-m-phenyl); 7.96 (d, 2H, J=8.43, aroyl-o-phenyl); 9.30 (s, 1H, amido -NH-). 
13C NMR (50 MHz, CDCl3) δ: 23.58; 31.72; 34.16; 45.88; 55.33; 64.56; 96.28; 97.43; 126.65; 
128.47; 134.70; 139.49; 154.63; 161.04; 170.04; 197.80. ESI-MS HR: 454.2707 (M +1), Calc. 
454.2706. 
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(5). 
C27H36N2O2, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (4-isopropyl-
phenyl)amide (0.74 mmol) and a corresponding amount of piperidine, 0.188 g of 5 was obtained, 
59.90 % yield, light yellow solid, m.p. = 106-108 ºC  (toluene). 1H NMR (200 MHz, CDCl3) δ: 
1.22 (d, 6H, J=7.30 Hz, i-PrCH3–phenylamide); 1.27(d, 6H, J=7.30 Hz, i-PrCH3-aroyl); 1.46 (m, 
2H, piperidinyl –CH2–); 1.63 (m, 4H, piperidinyl –CH2–); 2.57 (m, 4H, piperidinyl –CH2–); 
2.83-3.00 (overlapped m, 3H, i-PrCH and ABX); 3.71 (dd, 1H, J1,2=6.74 Hz, J1,3=16.18 Hz, 
ABX); 4.26 (t, 1H, J1,2=5.62 Hz, ABX); 7.16 (d, 2H, J=7.86 Hz, amido-m-phenyl); 7.32 (d, 2H, 
J=7.86 Hz, aroyl-m-phenyl); 7.46 (d, 2H, J=8.41, Hz amido-o-phenyl); 7.97 (d, 2H, J=7.86 Hz 
aroyl-o-phenyl); 9.39 (s, 1H, amido -NH-). 13C NMR (50 MHz, CDCl3) δ: 23.58; 23.94; 26.69; 
31.87; 33.49; 34.14; 51.02; 66.78; 95.70; 119.31; 126.61; 126.76; 128.49; 134.95; 135.55; 
144.55; 154.38; 170.38; 198.37. ESI-MS HR: 421.2838 (M +1), Calc. 421.2855. 
4.2.6. N-(4-Isopropylphenyl)-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-(1-imidazolyl)butanamide (6). 
C25H29N3O2, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (4-isopropyl-
phenyl)amide (0.74 mmol) and a corresponding amount of imidazole, 0.251 g of 6 was obtained, 
83.35 % yield, white solid, m.p. = 164-165 ºC (toluene). 1H NMR (200 MHz, CDCl3) δ: 1.17 (d, 
6H, J=7.45 Hz, i-PrCH3-phenylamide); 1.24 (d, 6H, J=6.09 Hz, i-PrCH3-aroyl); 2.75-3.01 
(overlapped m, 2H, i-PrCH3); 3.49 (dd, 1H, J1,2=5.65 Hz, J1,3=18.12 Hz, ABX); 4.10 (dd, 1H, 
J1,2=7.13 Hz, J1,3=17.24 Hz, ABX); 5.65 (t, 1H, J1,2=6.24 Hz, ABX); 7.09 (d, 2H, J=8.48 Hz, 
amido-m-phenyl); 7.14 (s, 1H, imidazolyl-CH); 7.21 (s, 1H, imidazolyl-CH); 7.27 (d, 2H, 
J=8.47, aroyl-m-phenyl); 7.45 (d, 2H, J=8.48 Hz, amido-o-phenyl); 7.62 (s, 1H, imidazolyl–CH); 
7.85 (d, 2H, J=8.47, aroyl-o-phenyl); 9.97 (s, 1H, amido -NH-). 13C NMR (50 MHz, CDCl3) δ: 
22.53; 23.91; 33.50; 34.21; 41.75; 56.68; 95.73; 118.02; 120.19; 126.76; 128.42; 129.55; 133.66; 
135.50; 137.41; 145.31; 155.53; 166.36; 195.82. ESI-MS HR: 404.2337 (M +1), Calc. 404.2338. 
4.2.7. N-(4-Isopropylphenyl)-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-(4-morpholinyl)butanamide 
(7). 
C26H34N2O3, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (4–isopropyl-
phenyl)amide (0.89 mmol) and a corresponding amount of morpholine, 7 was obtained, in 
quantitative yield, as yellow semi-solid. 1H NMR (200 MHz, CDCl3) δ: 1.22 (d, 6H, J=6.69 Hz, 
i-PrCH3-phenylamide); 1.26 (d, 6H, J=7.31 Hz, i-PrCH3-aroyl); 2.64 (t-like, 4H, J=4.26 Hz 
morpholinyl-CH2-); 2.79-3.06 (overlapped m, 3H, ABX and i-Pr-CH); 3.66-3.77 (overlapped m, 
5H, ABX and morpholinyl-CH2-); 4.27 (dd, 1H, J1,2=5.18 Hz, J1,3=9.44 Hz, ABX); 7.16 (d, 2H, 
J=8.83 Hz, amido-m-phenyl); 7.31 (d, 2H, J=7.62, aroyl-m-phenyl); 7.44 (d, 2H, J=8.22 Hz, 
amido-o-phenyl); 7.96 (d, 2H, J=8.52, aroyl-o-phenyl); 9.16 (s, 1H, amido -NH-). 13C NMR (50 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTMHz, CDCl3) δ: 23.56; 23.93; 32.14; 33.47; 34.16; 50.00; 65.15; 67.31; 95.70; 119.44; 126.69; 
126.83; 128.49; 135.24; 144.89; 154.69; 169.55; 197.86. ESI-MS HR: 423.2642 (M +1), Calc. 
423.2648. 
4.2.8. N-(4-Isopropylphenyl)-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-[1-(4-methylpiperazinyl)]-
butanamide (8). 
C27H37N3O2, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (4-isopropyl-
phenyl)amide (0.89 mol) and a corresponding amount of 1-methylpiperazine, 0.145 g of 8 was 
obtained, in quantitative yield, as yellow semi-solid. 1H NMR (200 MHz, CDCl3) δ: 1.22 (d, 6H, 
J=7.01 Hz, i-PrCH3-phenylamide); 1.26 (d, 6H, J=7.01 Hz, i-PrCH3-aroyl); 2.31 (s, 3H, 
piperazine-CH3); 2.87 (m, 1H, J1,2=6.72 Hz, J1,3=13.83 Hz, i-PrCH); 2.87 (overlapped m, 2H, 
ABX and i-PrCH); 2.53 (br, 4H, piperazine-CH2-); 2.68 (br, 4H, piperazine-CH2-); 3.70 (dd, 1H, 
J1,2=7.29 Hz, J1,3=16.34 Hz, ABX); 4.33 (t-like picks, J1,2=7.04 Hz, ABX);  7.16 (d, 2H, J=8.30 
Hz, amido-m-phenyl); 7.31 (d, 2H, J=8.30, aroyl-m-phenyl); 7.45 (d, 2H, J=8.80 Hz, amido-o-
phenyl); 7.95 (d, 2H, J=8.05, aroyl-o-phenyl); 9.21 (s, 1H, amido -NH-). 13C NMR (50 MHz, 
CDCl3) δ: 26.63; 23.99; 31.87; 33.55; 34.22; 45.94; 55.62; 64.80; 119.40; 126.66; 126.82; 
128.50; 134.87; 135.41; 144.78; 154.54; 169.81; 198.01. ESI-MS HR: 436.2965 (M +1), Calc. 
436.2964. 
4.2.9. N-Cyclohexyl-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-(1-piperidinyl)butanamide (9). 
C24H36N2O2, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid cyclohexylamide 
(0.83 mmol) and a corresponding amount of piperidine, 0.160 g of 9 was obtained, 49.74 % 
yield, yellow semi-solid. 1H NMR (200 MHz, CDCl3) δ: 1.25 (d, 6H, J=6.71Hz, i-PrCH3); 1.14-
1.45 (overlapped m, 8H, cyclohexyl-CH2-, piperidinyl-CH2-); 1.54-1.66 (overlapped m, 6H, 
cyclohexyl-CH2-, piperidinyl-CH2-); 1.78-3.77 (br, 2H, cyclohexyl-CH2-); 2.50 (t-like picks, 4H, 
J=5.97 Hz, piperidinyl-CH2-); 2.84 (dd, 1H, J1,2=5.11 Hz, J1,3=16.48 Hz, ABX); 2.95 (m, 1H, i-
PrCH); 3.63 (dd, 1H, J1,2=7.39 Hz, J1,3=16.19 Hz, ABX); 3.77 (m, 1H, cyclohexyl-CH-); 4.06 
(dd, 1H, J1,2=5.69 Hz, J1,3=9.66 Hz, ABX); 7.30 (d, 2H, J=7.96Hz, aroyl-m-phenyl); 7.95 (d, 2H, 
J=8.24Hz, aroyl-o-phenyl); 6.83 (d, 1H, J=13.14 Hz, amido-NH-); 13C NMR (50 MHz, CDCl3) 
δ: 23.58; 24.02; 24.60; 25.49; 26.60; 32.05; 32.90; 33.12; 34.14; 47.50; 50.91; 65.58; 126.56; 
128.47; 135.26; 154.14; 171.06. ESI-MS HR: 385.2855 (M +1), Calc. 385.2842.  
4.2.10. N-Cyclohexyl-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-(1-imidazolyl)butanamide (10). 
C22H29N3O2, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid cyclohexylamide 
(0.83 mol) and a corresponding amount of imidazole, 0.148 g of 10 was obtained, 48.14 % yield, 
orange semi-solid. 1H NMR (200 MHz, CDCl3) δ: 1.06-1.41 (m, 6H, cyclohexyl-CH2-); 1.25 (d, 
6H, J=7.28Hz, i-PrCH3);  1.61 (m, 2H, cyclohexyl-CH2-); 1.83 (br, 2H, cyclohexyl-CH2-);   2.95 
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); 4.02 (dd, 1H, J1,2=6.67 Hz, J1,3=17.90 Hz, ABX); 5.45 (t-like picks, 1H, J1,2=6.68 Hz, ABX);  
6.65 (d, 1H, J=7.86 Hz, amido-NH); 7.07 (s, 1H, imidazolyl-CH); 7.12 (s, 1H, imidazolyl-CH); 
7.30 (d, 2H, J=8.50Hz, aroyl-m-phenyl); 7.71 (s, 1H, imidazolyl-CH); 7.86 (d, 2H, J=8.49Hz, 
aroyl-o-phenyl); 13C NMR (50 MHz, CDCl3) δ: 23.51; 24.60; 25.24; 32.48; 34.20; 41.61; 48.82; 
56.39; 117.97; 126.81; 128.36; 129.31; 133.75; 137.28; 155.47; 167.34; 195.67. ESI-MS HR: 
368.2336 (M +1), Calc. 368.2338. 
4.2.11. N-Cyclohexyl-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-(4-morpholinyl)butanamide (11). 
C23H34N2O3, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid cyclohexylamide 
(0.94 mmol) and a corresponding amount of morpholine, 0.131 g of 11 was obtained, 35.92 % 
yield, pale orange solid, m.p. = 93-95 ºC (toluene). 1H NMR (200 MHz, CDCl3) δ: 1.09 (br, 6H, 
cyclohexyl -CH2-); 1.26 (d, 6H, J=11.26 Hz, i-PrCH3); 1.64 (br, 2H, cyclohexyl -CH2-); 1.86 
(br, 2H, cyclohexyl -CH2-); 2.58 (t, 4H,  J1,2=4.57 Hz, morpholino -CH2-); 2.86-2.99 (overlapped 
m, 2H, i-PrCH and ABX); 3.59-3.76 (overlapped m, 6H, ABX, morpholino -CH2-, and 
cyclohexyl -CH-); 4.07 (dd, 1H, J1,2=5.10 Hz, J1,3=7.84 Hz, ABX); 7.05 (d, 1H, J=7.84 Hz, 
amido-NH-); 7.31 (d, 2H, J=8.43, aroyl-m-phenyl); 7.94 (d, 2H, J=8.43, aroyl-o-phenyl). 13C 
NMR (50 MHz, CDCl3) δ: 23.60; 24.66; 25.46; 32.43; 32.92; 33.21; 34.20; 47.74; 50.02; 64.97; 
67.31; 126.67; 128.47; 135.01; 154.49; 170.20; 198.31. ESI-MS HR: 387.2639 (M +1), Calc. 
387.2648. 
4.2.12. N-Cyclohexyl-4-(4-isopropylphenyl)-4-oxo-2-(R,S)-[1-(4-methylpiperazinyl)butanamide 
(12). 
C24H37N3O2, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid cyclohexylamide 
(0.83 mmol) and a corresponding amount of 1-methylpiperazine, 0.045 g of 12 was obtained, 
13.46 % yield, yellow solid, m.p. = 101-103 ºC (toluene). 1H NMR (200 MHz, CDCl3) δ: 1.12-
1.39 (br, 6H, cyclohexyl -CH2-); 1.25 (d, 6H, J=6.97 Hz, i-PrCH3); 1.56-1.64 (br, 2H, 
cyclohexyl -CH2-); 1.86 (br, 2H, cyclohexyl –CH2-); 2.30 (s, 3H, -N-CH3); 2.42-2.51 (br, 4H, 
piperazine -CH2-); 2.60 (d-like, 4H, piperazine -CH2-); 2.83-2.99 (overlapped m, 2H, i-Pr-CH, 
ABX); 3.63 (dd, 1H, J1,2=7.94 Hz, J1,3=16.21 Hz, ABX); 3.77 (br, 1H, cyclohexyl -CH-);  4.14 
(dd, 1H, J1,2=5.16 Hz, J1,3=8.44 Hz, ABX); 7.11 (d-like, 1H, J=8.21 Hz, amido-NH); 7.30 (d, 
2H, J=8.44 Hz, aroyl-m-phenyl); 7.93 (d, 2H, J=8.44 Hz, aroyl-o-phenyl); 13C NMR (50 MHz, 
CDCl3) δ: 23.56; 24.58; 25.42; 31.90; 32.87; 33.14; 34.12; 45.81; 47.56; 55.42; 64.51; 126.54; 
128.42; 135.06; 154.25; 170.40; 198.48. ESI-MS HR: 400.2959 (M +1), Calc. 400.2964. 
4.2.13. 4-(2,4-Diisopropylphenyl)-N-(3,5-dimethoxyphenyl)-4-oxo-2-(R,S)-(1-piperidinyl)-
butanamide (13). 
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    C29H40N2O4, starting from ( )-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid (3,5-
dimethoxyphenyl)amide (0.76 mol) and a corresponding amount of piperidine, 13 was obtained,  
in quantitative yield, orange solid, m.p. = 99-101 ºC (toluene). 1H NMR: (500 MHz, CDCl3) δ: 
1.21-1.29 (overlapped m, 12H, i-PrCH3); 1.52 (m, 2H, piperidino -CH2-); 1.66 (m, 4H, piperidino 
-CH2-); 2.55 (m, 4H, piperidino -CH2-); 2.87-2.96 (overlapped m, 2H, i-PrCH and ABX); 3.45-
3.52 (overlapped m, 2H, i-PrCH and ABX); 3.77 (s, 6H, -OCH3); 4.20 (dd, 1H, J1,2=4.69 Hz, 
J1,3=8.04 Hz, ABX); 6.22 (t, 1H, J=2.07 Hz, amido-p-phenyl); 6.79 (s, 2H, amido-o-phenyl); 
7.26-7.27 (overlapped d and s, 2H, aroyl-m-phenyl); 7.63 (d, 1H, J=7.79 Hz, aroyl-o-phenyl); 
9.37 (s, 1H, amido -NH-). 13C NMR (125 MHz, CDCl3) δ: 22.85; 23.16; 23.75; 23.95; 24.42; 
26.73; 29.13; 34.26; 35.99; 44.50; 55.35; 66.27; 96.37; 97.39; 98.68; 123.16; 124.72; 127.97; 
136.51; 139.64; 148.34; 152.00; 161.05; 170.57; 203.13. ESI-MS HR: 481.3075 (M +1), Calc. 
481.3066. 
4.2.14. 4-(2,4-Diisopropylphenyl)-N-(3,5-dimethoxyphenyl)-4-oxo-2-(R,S)-(1-imidazolyl)butan-
amide (14). 
    C27H33N3O4, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid (3,5-
dimethoxyphenyl)amide (0.89 mmol) and a corresponding amount of imidazole, 0.220 g of 14 
was obtained, 52.94 % yield, orange solid, m.p. = 103-105 ºC (toluene). 1H NMR (200 MHz, 
CDCl3) δ: 1.11-1.26 (overlapped m, 12H, i-PrCH3); 2.91 (m, 1H, J1,2=8.69 Hz, J1,3=14.28 Hz, i-
Pr-CH); 3.31-3.50 (overlapped m, 2H, i-PrCH and ABX); 3.68 (s, 6H, -OCH3); 3.98 (dd, 1H, 
J1,2=7.45 Hz, J1,3=18.25 Hz, ABX); 5.66 (t, 1H, J1,2=7.19 Hz, ABX); 6.20 (br, 1H, amido-p-
phenyl); 6.81 (s, 1H, amido-m-phenyl); 6.82 (s, 1H, amido-m-phenyl); 7.01-7.10 (overlapped 
signals, 2H, aroyl-m-phenyl); 7.17 (s, 1H, imidazolyl -CH-); 7.24 (s, 1H, imidazolyl -CH-); 7.48 
(d, 1H, J=8.39, aroyl-o-phenyl); 7.70 (s, 1H, imidazolyl -CH-); 9.85 (s, 1H, amido -NH-). 13C 
NMR (50 MHz, CDCl3) δ: 23.62; 23.96; 28.99; 34.27; 45.08; 55.24; 57.19; 97.21; 98.30; 117.97; 
123.43; 124.92; 128.38; 128.93; 134.42; 137.41; 139.56; 148.99; 153.21; 160.92; 166.44; 
200.50. ESI-MS HR: 464.2532 (M +1), Calc. 464.2549. 
4.2.15. 4-(2,4-Diisopropylphenyl)-N-(3,5-dimethoxyphenyl)-4-oxo-2-(R,S)-(4-morpholinyl)-
butanamide (15). 
C28H38N2O5, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid (3,5-
dimethoxyphenyl)amide (1.00 mmol) and a corresponding amount of morpholine, 0.235 g of 15 
was obtained, 48.08 % yield, orange solid, m.p. = 126-128 ºC (toluene). 1H NMR (200 MHz, 
CDCl3) δ: 1.23-1.29 (overlapped m, 12H, i-PrCH3); 2.64 (t-like, 4H,  J1,2=3.90 Hz, morpholino -
CH2-); 2.88-2.98 (overlapped m, 2H, ABX and i-PrCH); 3.41-3.65 (overlapped m, 2H, ABX and 
–i-PrCH); 3.77 (overlapped picks, 10H, -OCH3 and morpholino-CH2-); 4.24 (dd, 1H, J1,2=3.89 
Hz, J1,3=7.24 Hz, ABX); 6.23 (br, 1H, amido-p-phenyl); 6.80 (s br, 2H, amido-o-phenyl); 7.12 
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phenyl); 9.22 (s, 1H, amido -NH-). 13C NMR (50 MHz, CDCl3) δ:  23.69; 24.14; 24.33; 29.11; 
34.23; 36.01; 43.72; 49.98; 55.31; 64.71; 65.66; 67.31; 96.50; 97.44; 103.18; 123.23; 124.77; 
128.01; 136.19; 139.38; 148.42; 152.25; 161.08; 169.67; 179.76; 194.87; 196.56; 202.57. ESI-
MS HR: 483.2845 (M +1), Calc. 483.2859. 
 
4.2.16. 4-(2,4-Diisopropylphenyl)-N-(3,5-dimethoxyphenyl)-4-oxo-2-(R,S)-[1-(4-methylpiper-
azinyl)]butanamide (16). 
C29H41N3O4, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid (3,5-
dimethoxyphenyl)amide (1.00 mmol) and a corresponding amount of 1-methylpiperazine, 0.298 
g of 16 was obtained, 59.37 % yield, orange solid, m.p. = 109-111 ºC (toluene). 1H NMR (200 
MHz, CDCl3) δ: 1.23-1.29 (overlapped m, 12H, i-PrCH3); 2.33 (s, 3H, N-CH3); 2.57 (br, 4H, 
piperazine -CH2-); 2.67 (br, 4H, piperazine -CH2-); 2.85-2.96 (overlapped m, 2H, ABX and i-
PrCH); 3.42-3.58 (overlapped m, 2H, ABX and i-PrCH); 3.78 (s, 6H, -OCH3); 4.28 (dd, 1H, 
J1,2=4.59 Hz, J1,3=8.52 Hz, ABX); 6.23 (t-like, 1H, J1,2=2.24 Hz, amido-p-phenyl); 6.79 (s, 1H, 
amido-o-phenyl); 6.80 (s, 1H, amido-o-phenyl); 7.11 (d, 1H, J=8.11, aroyl-m-phenyl); 7.27 (s, 
1H, aroyl-m-phenyl); 7.64 (d, 1H, J=8.12, aroyl-o-phenyl); 9.22 (s, 1H, amido -NH-). 13C NMR 
(50 MHz, CDCl3) δ: 23.71; 24.18; 24.31; 29.12; 34.21; 35.83; 45.85; 55.33; 55.50; 65.20; 96.32; 
97.45; 123.31; 124.70; 128.03; 163.35; 139.49; 148.32; 152.10; 161.04; 169.96; 202.81. ESI-MS 
HR: 496.3166 (M +1), Calc. 496.3170. 
4.2.17. 4-(2,4-Diisopropylphenyl)-N-(4-isopropylphenyl)-4-oxo-2-(R,S)-(1-piperidinyl)-
butanamide (17). 
C30H42N2O2, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid (4-isopropyl-
phenyl)amide (0.79 mmol) and a corresponding amount of piperidine, 0.160 g of 17 was 
obtained, 43.46% yield, orange semi-solid. 1H NMR (200 MHz, CDCl3) δ: 1.20-1.30 (overlapped 
d, 18H, i-PrCH3); 1.47 (br, 2H, piperidinyl -CH2-); 1.63 (br, 4H, piperidinyl -CH2-); 2.56 (t-like 
picks, 4H, J=14.06 Hz, piperidinyl -CH2-); 2.83-2.95 (overlapped m, 3H, ABX and i-PrCH); 
3.41-3.60 (overlapped m, 2H, ABX and i-PrCH); 4.21 (dd, 1H, J1,2=8.96 Hz, J1,3=17.91 Hz, 
ABX); 7.09 (d, 1H, J=8.95 Hz, aroyl-m-phenyl); 7.17 (d, 2H, J=7.68 Hz, amido-m-phenyl); 7.27 
(s, 1H, aroyl-m-phenyl); 7.46 (d, 2H, J=8.96Hz, amido-o-phenyl); 7.66 (d, 1H, J=8.96 Hz, aroyl-
o-phenyl); 9.32 (s, 1H, amido -NH-); 13C NMR (50 MHz, CDCl3) δ: 23.71; 23.96; 24.18; 24.36; 
26.69; 29.13; 33.52; 34.21; 36.13; 51.07; 66.06; 119.35; 123.19; 124.63; 126.80; 128.11; 135.61; 
144.58; 148.26; 151.94; 170.35; 203.30. ESI-MS HR: 463.3322 (M +1), Calc. 463.3319.  
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ACCEPTED MANUSCRIPT4.2.18. 4-(2,4-Diisopropylphenyl)-N-(4-isopropylphenyl)-4-oxo-2-(R,S)-(1-imidazolyl)-
butanamide (18). 
C28H35N3O2, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid (4-isopropyl-
phenyl)amide (0.79 mmol) and a corresponding amount of imidazole, 18 was obtained, in 
quantitative yield, orange semi-solid. 1H NMR(200 MHz, CDCl3) δ: 1.12-1.25 (overlapped d, 
18H, iPrCH3); 2.83-2.92 (overlapped m, 2H, i-Pr-CH); 3.36 (t-like, 1H, J1,2=6.71 Hz, i-Pr-CH); 
3.46 (dd, 1H, J1,2=5.25 Hz, J1,3=17.44 Hz, ABX); 4.00 (dd, 1H, J1,2=6.15 Hz, J1,3=17.89 Hz, 
ABX); 5.69 (br, 1H, ABX); 7.08 (d, 1H, J=7.71Hz, aroyl-m-phenyl); 7.12 (d, 2H, J=8.05Hz, 
amido-m-phenyl); 7.17 (s, 1H, imidazolyl -CH-); 7.24 (s br, 1H, imidazolyl -CH-); 7.26 (s, 1H, 
aroyl-m-phenyl); 7.44 (d, 2H, J=7.49Hz, amido-o-phenyl); 7.48 (d, 1H, J=8.05 Hz, aroyl-o-
phenyl); 7.77 (s, 1H, imidazolyl -CH-); 9.32 (s, 1H, amido -NH-); 13C NMR (125 MHz, CDCl3) 
δ: 23.68; 23.95; 24.07; 29.08; 33.58; 34.31; 45.12; 57.18; 117.93; 120.26; 123.51; 124.93; 
126.81; 128.31; 134.48; 135.17; 145.53; 148.96; 153.18; 166.18; 200.44. ESI-MS HR: 446.2806 
(M +1), Calc. 446.2808. 
4.2.19. 4-(2,4-Diisopropylphenyl)-N-(4-isopropylphenyl)-4-oxo-2-(R,S)-(4-morpholinyl)butan-
amide (19). 
C29H40N2O3, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoicacid(4-isopropyl-
phenyl)amide (0.79 mmol) and a corresponding amount of morpholine, 19 was obtained, in 
quantitative yield, orange semi-solid. 1H NMR (200 MHz, CDCl3) δ: 1.23-1.30 (overlapped d, 
18H, i-PrCH3); 2.64 (t-like picks, 4H, morpholino -CH2-); 2.84-2.97 (overlapped m, 3H, ABX 
and i-PrCH); 3.40-3.64 (overlapped m, 2H, i-PrCH and ABX); 3.77 (br, 4H, morpholino -CH2-); 
4.24 (dd, 1H, J1,2=4.43 Hz, J1,3=8.07 Hz, ABX); 7.09-7.13 (d-like signal, 1H, aroyl-m-phenyl); 
7.18 (d, 2H, J=8.41 Hz, J= 8.41, amido-m-phenyl); 7.28 (s, 1H, aroyl-m-phenyl); 7.46 (d, 2H, J= 
8.41 Hz, amido-o-phenyl); 7.65 (d, 1H, J=7.84 Hz, aroyl-o-phenyl); 9.16 (s, 1H, amido -NH-); 
13C NMR (50 MHz, CDCl3) δ: 23.69; 23.94; 24.18; 24.29; 29.15; 33.50; 34.21; 36.20; 50.02; 
65.44; 67.31; 119.42; 123.25; 124.70; 126.85; 128.13; 128.98; 135.30; 136.21; 144.89; 148.35; 
152.19; 169.45; 202.72. ESI-MS HR: 465.3114 (M +1), Calc. 465.3117. 
4.2.20. 4-(2,4-Diisopropylphenyl)-N-(4-isopropylphenyl)-4-oxo-2-(R,S)-[1-(4-methyl-
piperazinyl)]butanamide (20). 
C30H43N3O2, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoicacid (4-isopropyl-
phenyl)amide (0.79 mmol) and a corresponding amount of 1-methylpiperazine, 20 was obtained, 
in quantitative yield, orange semi-solid. 1H NMR (200 MHz, CDCl3) δ: 1.21-1.29 (overlapped d, 
18H, i-PrCH3); 2.32 (s, 3H, N-CH3); 2.53 (br, 4H, piperazine -CH2-); 2.67 (br, 4H, piperazine -
CH2-); 2.80-2.97 (overlapped m, 3H, ABX and i-PrCH); 3.38-3.61 (overlapped m, 2H, ABX and 
i-PrCH); 4.28 (dd, 1H, J1,2=4.53 Hz, J1,3=7.76 Hz, ABX); 7.07-7.12 (d-like signals, 1H, aroyl-m-
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ACCEPTED MANUSCRIPTphenyl); 7.17 (d, 2H, J=8.57 Hz, amido-m-phenyl); 7.26 (s, 1H, aroyl-m-phenyl); 7.46 (d, 2H, 
J=8.57, amido-o-phenyl); 7.63 (d, 1H, J=8.20 Hz, aroyl-o-phenyl); 9.16 (s, 1H, amido -NH-); 
13C NMR (50 MHz, CDCl3) δ: 23.71; 23.96; 24.22; 24.29; 29.17; 33.50; 34.21; 36.00; 45.88; 
55.52; 65.02; 119.39; 123.25; 124.63; 126.83; 128.18; 135.43; 136.39; 144.75; 148.24; 152.05; 
169.75; 202.97. ESI-MS HR: 478.3429 (M +1), Calc. 478.3428. 
4.2.21. N-Cyclohexyl-4-(2,4-diisopropylphenyl)-4-oxo-2-(R,S)-(1-piperidinyl)butanamide (21). 
C27H42N2O2, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid cyclohexyl-
amide (0.88 mmol) and a corresponding amount of piperidine, 0.151 g of 21 was obtained, 40.22 
% yield, white solid, m.p. = 105-107 ºC (toluene). 1H NMR (200 MHz, CDCl3) δ: 1.09-1.46 
(overlapped m, 8H, cyclohexyl -CH2- and piperidinyl -CH2-); 1.22-1.28 (overlapped d, 12H, i-
PrCH3); 1.54-1.70 (overlapped m, 6H, piperidinyl-CH2- and cyclohexyl-CH2-); 1.84 (br, 2H, 
cyclohexyl-CH2-); 2.47 (t-like, 4H, J=6.97Hz, piperidinyl -CH2-); 2.97 (dd, 1H, J1,2=4.65 Hz, 
J1,3=16.27 Hz, ABX); 2.91 (m, 1H, i-PrCH); 3.35-3.53 (overlapped m, 2H, ABX and i-PrCH); 
3.74 (m, 1H, cyclohexyl -CH-); 4.03 (dd, 1H, J1,2=4.59 Hz, J1,3=17.91 Hz, ABX); 7.09 (d, 1H, 
J=7.83Hz, aroyl-m-phenyl); 7.24 (s, 1H, aroyl-m-phenyl); 7.66 (d, 1H, J=7.83Hz, aroyl-o-
phenyl); 6.75 (d, 1H, J=13.78 Hz, amido -NH-);. 13C NMR (50 MHz, CDCl3) δ: 22.31; 22.43; 
23.71; 24.00; 24.18; 24.31; 24.58; 25.47; 26.53; 29.12; 32.88; 33.14; 34.18; 36.36; 44.43; 47.41; 
50.89; 65.33; 95.73; 123.17; 124.47; 128.14; 136.70; 170.96; 203.83. ESI-MS HR: 427.3323 (M 
+1), Calc. 427.3325.  
4.2.22. N-Cyclohexyl-4-(2,4-diisopropylphenyl)-4-oxo-2-(R,S)-(1-imidazolyl)butanamide (22). 
C25H35N3O2, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid cyclohexyl-
amide (0.88 mmol) and a corresponding amount of imidazole, 0.170 g of 22 was obtained, 47.17 
% yield, white solid, m.p. = 123-125 ºC (toluene). 1H NMR (200 MHz, CDCl3) δ: 1.04-1.35 
(overlapped m, 6H, cyclohexyl -CH2-); 1.12-1.26 (overlapped d, 12H, i-PrCH3); 1.53-1.69 (br, 
2H, cyclohexyl -CH2-); 1.83 (br, 2H, cyclohexyl -CH2-); 2.91 (m, 1H, J1,2=6.67 Hz, J1,3=13.34 
Hz, i-Pr-CH); 3.25-3.45 (overlapped m, 2H, ABX and -i-PrCH); 3.73 (m, 1H, cyclohexyl -CH-); 
3.96 (dd, 1H, J1,2=6.19 Hz, J1,3=17.98 Hz, ABX); 5.40 (t, 1H, J1,2=6.67 Hz, ABX); 6.32 (s br, 
1H, amido -NH-); 7.06-7.11 (overlapped m, 2H, aroyl-m-phenyl and imidazolyl -CH-); 7.24 (d-
like, 1H, aroyl-m-phenyl); 7.46 (d, 1H, J=7.81, aroyl-o-phenyl); 7.57 (s, 1H, imidazolyl -CH-); 
13C NMR (50 MHz, CDCl3) δ: 26.62; 23.94; 24.04; 24.62; 25.24; 29.01; 32.48; 34.23; 45.19; 
48.80; 56.64; 95.73; 117.73; 123.39; 124.85; 128.13; 130.09; 134.70; 137.43; 148.72; 153.01; 
167.34; 200.70. ESI-MS HR: 410.2813 (M +1), Calc. 410.2802 
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ACCEPTED MANUSCRIPT4.2.23. N-Cyclohexyl-4-(2,4-diisopropylphenyl)-4-oxo-2-( ,S)-(4-morpholinyl)butanamide (23). 
C26H40N2O3, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid cyclohexyl-
amide (1.00 mmol) and a corresponding amount of morpholine, 0.372 g of 23 was obtained, 
84.55 % yield, white solid, m.p. = 142-144 ºC (toluene). 1H NMR (200 MHz, CDCl3) δ: 1.11-
1.41 (br, 6H, cyclohexyl -CH2-); 1.23-1.29 (overlapped d, 12H, i-PrCH3); 1.65 (br, 2H, 
cyclohexyl -CH2-); 1.86 (br, 2H, cyclohexyl -CH2-); 2.56 (t-like, 4H,  J1,2=4.40 Hz, morpholino -
CH2-); 2.78-2.95 (overlapped m, 2H, ABX and i-PrCH); 3.35-3.58 (overlapped m, 2H, ABX and 
i-PrCH); 3.72 (q-like, 4H, J1,2=3.64 Hz, J1,3=8.80 Hz, morpholino -CH2-); 3.79 (m, 1H, 
cyclohexyl -CH-); 4.05 (dd, 1H, J1,2=4.43 Hz, J1,3=8.07 Hz, ABX); 7.07-7.12 (overlapped m, 
aroyl-m-phenyl and amido -NH-); 7.24 (br, 1H, aroyl-m-phenyl); 7.64 (d, 1H, J=7.81, aroyl-o-
phenyl); 13C NMR (50 MHz, CDCl3) δ: 23.71; 24.22; 24.29; 24.64; 25.46; 29.19; 32.92; 33.25; 
34.21; 36.62; 47.67; 49.96; 64.78; 67.26; 123.26; 124.57; 128.18; 136.41; 148.12; 152.03; 
170.09; 203.21. ESI-MS HR: 429.3123 (M +1), Calc. 429.3112. 
4.2.24. N-Cyclohexyl-4-(2,4-diisopropylphenyl)-4-oxo-2-(R,S)-[1-(4-methylpiperazinyl-)]butan-
amide (24). 
C27H43N3O2, starting from (E)-4-(2,4-diisopropylphenyl)-4-oxo-2-butenoic acid cyclohexyl-
amide (1.00 mmol) and a corresponding amount of 1-methylpiperazine, 0.256 g of 24 was 
obtained, 56.47 % yield, white solid, m.p. = 96-98 ºC (toluene). 1H NMR (200 MHz, CDCl3) δ: 
1.15-1.39 (br, 6H, cyclohexyl -CH2-); 1.22-1.27 (overlapped d, 12H, i-PrCH3); 1.65 (br, 2H, 
cyclohexyl -CH2-); 1.86 (br, 2H, cyclohexyl -CH-); 2.33 (s, 3H, piperazine-N-CH3); 2.52 (br, 
4H, piperazine -CH2-); 2.60 (br, 4H, piperazine -CH2-); 2.76-2.96 (overlapped m, 2H, ABX and 
–i-PrCH); 3.34-3.55 (overlapped m, 2H, ABX and i-PrCH); 3.76 (m, 1H, cyclohexyl -CH-); 4.10 
(dd, 1H, J1,2=4.50 Hz, J1,3=9.00 Hz, ABX); 7.04-7.11(overlapped m, aroyl-m-phenyl and 
cyclohexyl-NH); 7.24 (s, 1H, aroyl-m-phenyl); 7.64 (d, 1H, J=8.04, aroyl-o-phenyl); 13C NMR 
(50 MHz, CDCl3) δ: 23.67; 24.18; 24.58; 25.42; 29.15; 32.87; 33.18; 34.16; 36.36; 45.68; 47.56; 
55.32; 64.31; 123.31; 124.43; 128.14; 136.54; 147.91; 151.81; 170.26; 203.41. ESI-MS HR: 
442.3436 (M +1), Calc. 442.3428. 
4.2.25. N-(3,5-Dimethoxyphenyl)-4-oxo-2-(R,S)-(1-piperidinyl)-4-(5,6,7,8-tetrahydronaphtha-
lenyl)butanamide (25). 
C27H43N3O2, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphthalenyl)-2-butenoic acid 
(3,5-dimethoxyphenyl)-amide (0.82 mmol) and a corresponding amount of piperidine, 0.239 g of 
25 was obtained, 64.61% yield, pale yellow solid, m.p. = 135 ºC (toluene). 1H NMR (200 MHz, 
CDCl3) δ: 1.48 (q-like signals, 2H, piperidinyl -CH2-); 1.65 (q-like signals, 4H, piperidinyl -CH2-
); 1.81 (br, 4H, tetralinoyl -CH2-); 2.57 (t-like signals, 4H, piperidinyl -CH-); 2.82 (br, 4H, 
tetralinoyl -CH2-); 3.00 (dd, 1H, J1,2 = 5.06, J1,3 = 16.85, ABX); 3.68 (dd, 1H, J1,2 = 7.30, J1,3 = 
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ACCEPTED MANUSCRIPT17.41, ABX); 3.77 (s, 6H, -OCH3); 4.25 (dd, 1H, J1,2 = 5.06, J1,3 = 6.74, ABX); 6.22 (t-like 
signals, 1H, amido-p-phenyl); 6.79 (s, 1H, amido-o-phenyl); 6.80 (s, 1H, amido-o-phenyl); 7.15 
(d, 1H, J = 8.99, aroyl-m-phenyl); 7.73 (m, 2H, aroyl-o-phenyl); 7.74 (m, 2H, aroyl-o-phenyl); 
9.48 (s, 1H, amide -NH-). 13C NMR (50 MHz, CDCl3) δ: 22.34; 22.54; 22.76; 22.89; 23.89; 
26.73; 29.32; 29.55; 31.92; 44.50; 51.04; 55.33; 65.57; 96.34; 97.37; 125.30; 129.14; 129.31; 
134.42; 137.39; 139.65; 143.16; 161.06; 170.71; 198.40. ESI-MS HR: 451.2594 (M +1), Calc. 
451.2591.  
 
4.2.26. N-(3,5-Dimethoxyphenyl)-4-oxo-2-(R,S)-(1-imidazolyl)-4-(5,6,7,8-tetrahydronaphtha-
lenyl)butanamide (26). 
         C25H27N3O4, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphthalenyl)-2-butenoic acid 
(3,5-dimethoxyphenyl)amide (0.82 mmol) and a corresponding amount of imidazole, 0.279 g of 
26 was obtained, 78.49 % yield, white solid, m.p. = 166 ºC. 1H NMR: (200 MHz, CDCl3) δ: 1.80 
(br, 4H, tetralinoyl -CH2-); 2.78 (br, 4H, tetralinoyl -CH2-); 3.48 (dd, 1H, J1,2 = 5.33, J1,3 = 
17.69, ABX); 3.73 (s, 6H, -OCH3); 4.07 (dd, 1H, J1,2 = 7.58, J1,3 = 17.41, ABX); 5.58 (t-like 
signals, 1H, ABX); 6.17 (sb, 1H, amido-p-phenyl); 6.76 (sb, 2H, amido-o-phenyl); 6.98 (s, 1H, 
imidazolyl -CH-); 7.07 (d, 1H, J=8.43Hz, aroyl-m-phenyl); 7.17(s, 1H, imidazolyl -CH-); 7.58 
(br, 2H, aroyl-o-phenyl); 7.77 (s, 1H, imidazolyl -CH-); 9.99 (s, 1H, amido -NH-). 13C NMR (50 
MHz, CDCl3) δ: 22.47; 22.62; 29.08; 29.46; 41.41; 55.10; 56.63; 96.95; 98.05; 117.87; 124.98; 
128.80; 128.94; 129.40; 133.06; 136.94; 137.59; 139.40; 144.27; 160.75; 196.22. ESI-MS HR: 
434.2084 (M +1), Calc. 434.2074.  
 
4.2.27. N-(3,5-Dimethoxyphenyl)-4-oxo-2-(R,S)-(4-morpholinyl)-4-(5,6,7,8-tetrahydronaphtha-
lenyl)butanamide (27). 
C26H32N2O5, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphthalenyl)-2-butenoic acid 
(3,5-dimethoxyphenyl)amide (1.00 mmol) and a corresponding amount of morpholine, 0.261 g 
of 27 was obtained, 52.69 % yield, white solid, m.p. = 179-181 ºC (toluene). 1H NMR (200 
MHz, CDCl3) δ: 1.81 (br, 4H, tetralinoyl -CH2-); 2.65 (t-like, 4H, J1,2=4.41 Hz, morpholino -
CH2-); 2.81 (br, 4H, tetralinoyl -CH2-); 3.04 (dd, 1H, J1,2=4.99 Hz, J1,3=16.75 Hz, ABX); 3.64-
3.89 (overlapped signals, 11H, ABX, -OCH3 and morpholino -CH2-); 4.24 (t-like, 1H, J1,2=5.06 
Hz, ABX); 6.23 (t-like, 1H, J1,2=2.29 Hz, amido-p-phenyl); 6.78 (s, 1H, amido-o-phenyl); 6.79 
(s, 1H, amido-o-phenyl); 7.15 (d, 1H, J=9.00 Hz, aroyl-m-phenyl); 7.72 (br, 2H, aroyl-o-phenyl); 
9.22 (s, 1H, amido -NH-). 13C NMR (50 MHz, CDCl3) δ: 22.73; 22.87; 29.32; 29.57; 32.16; 
50.02; 55.35; 66.02; 67.35; 95.73; 96.48; 97.46; 125.27; 129.14; 129.38; 134.21; 137.48; 139.40; 
143.42; 161.08; 169.82; 197.86. ESI-MS HR: 453.2387 (M +1), Calc. 453.2389. 
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ACCEPTED MANUSCRIPT4.2.28. N-(3,5-Dimethoxyphenyl)-4-oxo-2-(R,S)-[1-(4-methylpiperazinyl)]-4-(5,6,7,8-tetra-
hydronaphthalenyl)butanamide (28). 
C27H35N3O4, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphthalenyl)-2-butenoic acid 
(3,5-dimethoxyphenyl)amide (0.82 mmol) and a corresponding amount of 1-methylpiperazine, 
0.247 g of 28 was obtained, 64.42 % yield, pale yellow solid, m.p. = 106-108 ºC (toluene). 1H 
NMR (200 MHz, CDCl3) δ: 1.81 (br, 4H, tetralinoyl -CH2-); 2.34 (s, 3H, piperazine-N-CH3-); 
2.55 (br, 4H, piperazine -CH2-); 2.69 (br, 4H, piperazine -CH2-); 2.81 (br, 4H, tetralinoyl -CH2-
); 3.03 (dd, 1H, J1,2=4.96 Hz, J1,3=17.37 Hz, ABX); 3.67 (dd, 1H, J1,2=7.14 Hz, J1,3=17.37 Hz, 
ABX); 3.77 (s, 6H, -OCH3); 4.31 (dd, 1H, J1,2=4.96 Hz, J1,3=9.31 Hz, ABX); 6.23 (br, 1H, 
amido-p-phenyl); 6.79 (s, 1H, amido-o-phenyl); 6.80 (s, 1H, amido-o-phenyl); 7.14 (d, 1H, 
J=8.57 Hz, aroyl-m-phenyl); 7.71-7.73 (overlapped signals, 2H, aroyl-o-phenyl); 9.29 (s, 1H, 
amido -NH-); 13C NMR (50 MHz, CDCl3) δ: 22.73; 22.87; 29.30; 29.55; 31.86; 45.76; 55.35; 
55.50; 64.51; 96.30; 97.50; 125.25; 129.14; 129.33; 134.30; 137.41; 139.52; 143.31; 161.06; 
170.07; 198.04. ESI-MS HR: 466.2707 (M +1), Calc. 466.2706. 
 
4.2.29. N-(4-Isopropylphenyl)-4-oxo-2-(R,S)-(1-piperidinyl)-4-(5,6,7,8-tetrahydronaphthalenyl)-
butanamide (29). 
C28H36N2O2, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphthalenyl)-2-butenoic acid (4-
isopropylphenyl)amide (0.86 mmol) and a corresponding amount of piperidine, 0.373 g of 29 
was obtained, in quantitative yield, as yellow semi-solid. 1H NMR (200 MHz, CDCl3) δ: 1.22 (d, 
6H, J = 7.09, 4-i-PrCH3); 1.47 (q, 2H, J1,2 = 5.38, J1,3= 10.75, piperidine -CH2-); 1.64 (q, 4H, J1,2 
= 5.37, J1,3 = 10.75, piperidine -CH2-); 1.80 (br, 4H, tetralinoyl -CH2-); 2.57 (t, 4H, J1,2 = 5.07, 
piperidine -CH2-); 2.80 (br, 5H, tetralinoyl -CH2- and 4-i-Pr-CH); 2.96 (dd, 1H, J1,2 = 5.02, J1,3 = 
19.07, ABX); 3.68 (dd, 1H, J1,2 = 6.91, J1,3 = 16.57, ABX); 4.25 (t, 1H, J1,2 = 5.56, ABX); 7.14 
(d, 1H, J = 8.51, aroyl-m-phenyl); 7.16 (d, 2H, J = 8.06, amido-m-phenyl); 7.46 (d, 1H, J = 8.51, 
amido-o-phenyl); 7.73 (s, 1H, aroyl-o-phenyl); 7.76 (s, 1H, aroyl-o-phenyl); 9.40 (s, 1H, amido -
NH-). 13C NMR (50 MHz, CDCl3) δ: 22.76; 22.89; 23.94; 26.69; 29.30; 29.53; 31.96; 33.49; 
51.04; 65.71; 95.70; 119.29; 125.30; 126.76; 129.13; 134.53; 135.57; 137.34; 143.02; 144.53; 
170.44; 198.59. ESI-MS HR: 433.2868 (M +1), Calc. 433.2849.  
 
4.2.30. N-(4-Isopropylphenyl)-4-oxo-2-(R,S)-(1-imidazolyl)-4-(5,6,7,8-tetrahydronaphthalenyl)-
butanamide (30). 
C26H29N3O2, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphthalenyl)-2-butenoic acid (4-
isopropylphenyl)amide (0.86 mmol) and a corresponding amount of imidazole, 0.100 g of 30 
was obtained, 28.00 % yield, as yellow solid, m.p. 92°C. 1H NMR (200 MHz, CDCl3) δ: 1.17 (d, 
6H, J1,2 = 7.31, i-PrCH3); 1.78 (br, 4H, tetralinoyl -CH2-); 2.75-2.78 (5H, overlapped signals, 4-
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ACCEPTED MANUSCRIPTi-Pr-CH- and tetralinoyl -CH2-); 3.48 (dd, 1H, J1,2 = 5.61, J1,3 = 17.97, ABX); 4.08 (dd, 1H, J1,2 = 
7.30, J1,3 = 17.41, ABX); 5.64 (dd, 1H, J1,2 = 5.61, J1,3 = 7.30, ABX); 7.08 (d, 2H, J = 8.43, 
amido-m-phenyl); 7.13 (br, 2H, imidazolyl -CH-); 7.20 (s, 1H, aroyl-m-phenyl); 7.44 (d, 2H, J = 
8.42, amido-o-phenyl); 7.60 (br, 1H, imidazolyl -CH-); 7.62 (br, 2H, aroyl-o-phenyl); 9.95 (s, 
1H, amido -NH-). 13C NMR (50 MHz, CDCl3) δ: 22.615; 22.761; 23.908; 29.224; 29.588; 
33.503; 41.751; 56.699; 118.057; 120.169; 125.122; 126.761; 129.091; 129.492; 133.279; 
135.500; 137.394; 137.648; 144.185; 145.277; 166.452; 196.130. ESI-MS HR: 416.2342 (M +1), 
Calc. 416.2333. 
 
4.2.31. N-(4-Isopropylphenyl)-4-oxo-2-(R,S)-(4-morpholinyl)-4-(5,6,7,8-tetrahydronaphtha-
lenyl)butanamide (31). 
C27H34N2O3, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphthalenyl)-2-butenoic acid (4-
isopropylphenyl)amide (0.86 mmol) and a corresponding amount of morpholine, 0.365 g of 31 
was obtained, 97.28 % yield, as white solid, m.p. 129-131°C (toluene). 1H NMR (200 MHz, 
CDCl3) δ: 1.22 (d, 6H, J=6.52 Hz, i-PrCH3); 1.81 (br, 4H, tetralinoyl -CH2-); 2.65 (t-like, 4H,  
J1,2=4.53 Hz, morpholino -CH2-); 2.81 (br, 5H, tetralinoyl -CH2- and i-PrCH); 3.33 (dd, 1H, 
J1,2=5.00 Hz, J1,3=16.92 Hz, ABX); 3.65-3.77 (overlapped m, 5H, morpholino -CH2- and ABX); 
4.27 (dd, 1H, J1,2=5.72 Hz, J1,3=9.05 Hz, ABX); 7.12-7.19 (overlapped d, 3H, amido-m-phenyl 
and aroyl-m-phenyl); 7.42 (d, 2H, J=8.61 Hz, amido-o-phenyl); 7.72 (br, 2H, aroyl-o-phenyl); 
9.17 (s, 1H, amido -NH-). 13C NMR (50 MHz, CDCl3) δ: 22.73; 22.85; 23.93; 29.28; 29.53; 
32.21; 33.49; 50.04; 65.09; 67.33; 119.39; 125.25; 126.81; 129.34; 134.30; 135.30; 137.43; 
143.31; 144.86; 169.56; 198.02. ESI-MS HR: 435.2654 (M +1), Calc. 435.2648. 
 
4.2.32. N-(4-Isopropylphenyl)-4-oxo-2-(R,S)-[1-(4-methylpiperazinyl)]-4-(5,6,7,8-tetrahydro-
naphthalenyl)butanamide (32). 
       C28H37N3O2, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphthalenyl)-2-butenoic acid (4-
isopropylphenyl)amide (1.15 mmol) and a corresponding amount of 1-methylpiperazine, 0.432 g 
of 32 was obtained, 83.83 % yield, as orange semi-solid. 1H NMR (200 MHz, CDCl3) δ:1.22 (d, 
6H, J=6.60, i-PrCH3); 1.81(br, 4H, tetralinoyl -CH2-); 2.32 (s, 3H, piperazine-N-CH3); 2.52 (br, 
4H, piperazine -CH2-); 2.68 (br, 4H, piperazine -CH2-); 2.80 (br, 4H, tetralinoyl -CH2-); 2.96 (t-
like, 1H, J1,2=2.73, ABX); 2.96 (m, 1H, i-PrCH); 3.68 (dd, 1H, J1,2=7.16 Hz, J1,3=16.93 Hz, 
ABX); 4.33 (dd, 1H, J1,2=5.16 Hz, J1,3=7.04, ABX); 7.13 (d, 1H, J=8.11, aroyl-m-phenyl); 7.17 
(d, 2H, J=8.52, amido-m-phenyl); 7.46 (d, 2H, J=8.52, amido-o-phenyl); 7.72 (s, 1H, aroyl-o-
phenyl); 7.73 (d, 1H, J=5.41, aroyl-o-phenyl); 9.24 (s, 1H, amido -NH-). 13C NMR (50 MHz, 
CDCl3) δ:22.76; 22.91; 23.98; 29.31; 29.57; 31.88; 33.52; 44.30; 45.92; 55.59; 64.67; 119.37; 
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ACCEPTED MANUSCRIPT125.28; 126.83; 129.16; 129.33; 134.44; 135.44; 137.39; 143.20; 144.75; 168.89; 198.27. ESI-
MS HR: 448.2966 (M +1), Calc. 448.2964. 
4.2.33. N-Cyclohexyl-4-oxo-2-(R,S)-1-piperidinyl-4-(5,6,7,8-tetrahydronaphtalenyl)butanamide 
(33):  
      C25H36N2O2, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphtalenyl)-2-butenoic acid 
cyclohexylamide (0.96 mmol) and a corresponding amount of piperidine, 0.200 g of 33 was 
obtained, 52.35 % yield, as pale yellow solid, m.p. 78° C (toluene). 1H NMR (500 MHz, CDCl3) 
δ: 1.19 (m, 2H, ax C2, cyclohexyl -CH-); 1.36 (m, 2H, ax C3, cyclohexyl -CH-); 1.44 (m, 1H, ax 
C4, cyclohexyl -CH-); 1.55 (m, 4H, C3, piperidine -CH2-); 1.60 (m, 1H, eq C4, cyclohexyl -CH-
); 1.62 (m, 2H, C4, piperidine -CH2-); 1.68 (m, 2H, eq C3, cyclohexyl -CH-); 1.80 (d-like signal, 
4H, β-tetralinyl); 1.86 (m, 2H, eq C2, cyclohexyl -CH-); 2.49 and 2.54 (m, br, 4H, piperidine -
CH-); 2.80 (d-like signal, 4H, β-tetralinyl); 2.87 (dd, 1H, J1,2 = 5.31, J1,3 = 16.26, ABX); 3.60 
(dd, 1H, J1,2 = 7.19, J1,3 = 16.26, ABX); 3.75 (d-like signal, 1H, cyclohexyl -CH-); 4.06 (dd, 1H, 
J1,2 = 5.32, J1,3 = 7.04, ABX); 7.13 (d, 1H, J = 8.29, aroyl-m-phenyl); 7.28 (sb, 1H, amido -NH-); 
7.72 (overlapped d and s, 2H, aroyl-o-phenyl ; 13C NMR (125 MHz, CDCl3) δ: 22.61; 22.84; 
22.88; 22.96; 24.06; 24.63; 25.44; 25.54; 26.65; 29.35; 29.57; 32.12; 32.94; 33.16; 44.66; 47.50; 
50.95; 65.45; 125.28; 129.08; 129.21; 134.82; 137.26; 142.78; 171.08; 199.07. ESI-MS HR: 
397.2866 (M +1), Calc. 397.2849. 
4.2.34. N-Cyclohexyl-4-oxo-2-(R,S)-1-imidazolyl-4-(5,6,7,8-tetrahidronaphtalenyl)butanamide 
(34):  
C23H29N3O2, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphtalenyl)-2-butanoic acid 
cyclohexyl amide (0.96 mmol) and a corresponding amount of imidazole, 0.210 g of 34 was 
obtained, 57.64 % yield, as white solid, m.p. 98° C (toluene). 1H NMR (200 MHz, CDCl3) δ: 
1.00-1.42 (m, 6H, 3,4-cyclohexyl -CH2-); 1.48-1.73 (m, 4H, 2-cyclohexyl -CH2-); 1.79 (br, 4H, 
tetralinoyl -CH2-); 2.78 (br, 4H, tetralinoyl -CH2-); 3.47 (dd, 1H, J1,2 = 5.80, J1,3 = 17.88, ABX); 
3.61-3.83 (m, 1H, 1-cyclohexyl -CH-); 4.02 (dd, 1H, J1,2 = 8.21, J1,3 = 18.84, ABX); 5.42 (t, 1H, 
J1,2 = 5.65, ABX); 6.80 (d-like signal, 1H, amido -NH-); 7.09 (d, 1H, J = 7.20, aroyl-m-phenyl); 
7.14-7.29 (m, 3H, imidazolyl -CH-); 7.62 (br, 2H, aroyl-m-phenyl). 13C NMR (50 MHz, CDCl3) 
δ: 22.58; 22.73; 24.60; 25.22; 29.17; 29.53; 32.47; 41.59; 48.74; 56.28; 95.70; 117.89; 125.05; 
128.98; 129.40; 129.64; 133.39; 137.25; 137.57; 144.00; 167.42; 195.96. ESI-MS HR: 380.2337 
(M +1), Calc. 380.2332. 
4.2.35. N-Cyclohexyl-2-(R,S)-4-morpholinyl-4-oxo-4-(5,6,7,8-tetrahydro-2-naphthalenyl)butan-
amide (35): 
      C24H34N2O3, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphtalenyl)-2-butan cyclohexyl 
amide (0.96 mmol) and a corresponding amount of morpholine, 0.250 g of 35 was obtained, 
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ACCEPTED MANUSCRIPT65.12 % yield, as white solid, m.p. 106-108°C (toluene). 1H NMR (500 MHz, CDCl3) δ: 1.14-
1.24 (m, 3H, cyclohexyl -CH2-); 1.32-1.40 (m, 3H, cyclohexyl -CH2-); 1.58-1.62 (m, 1H, 
cyclohexyl-CH2-); 1.65-1.71 (m, 3H, cyclohexyl -CH2-); 1.81 (m, 4H, β-tetralinyl); 1.87 (m, 2H, 
cyclohexyl -CH2-); 2.58 (m, 4H, morpholinyl -CH2-); 2.80 (m, 4H, β-tetralinyl); 2.92 (dd, 1H, 
J1,2 = 5.16, J1,3 = 16.64, ABX); 3.63 (dd, 1H, J1,2 = 7.08, J1,3 = 16.45, ABX); 3.68 (m, 1H, 
cyclohexyl -CH-); 3.74 (m, 4H, morpholinyl -CH2-); 4.06 (dd, 1H, J1,2 = 5.16, J1,3 = 7.07, ABX); 
7.23 (m, 1H, amido -NH-); 7.70-7.71 (overlapped s and d, 2H, aroyl-o-phenyl); 13C NMR (125 
MHz, CDCl3) δ: 22.83; 22.96; 24.69; 25.50; 29.37; 29.61; 32.52; 32.97; 33.26; 47.74; 50.07; 
64.85; 67.35; 125.27; 128.20; 129.01; 129.09; 129.31; 134.59; 137.38; 143.11; 170.21; 198.46. 
ESI-MS HR: 399.2640 (M +1), Calc. 399.2648. 
4.2.36. N-Cyclohexyl-2-(R,S)-[1-(4-methylpiperazinyl)]-4-oxo-4-(5,6,7,8-tetrahydronaphthalen-
yl)butanamide (36): 
      C25H37N3O2, starting from (E)-4-oxo-4-(5,6,7,8-tetrahydronaphtalenyl)-2-butanoic acid 
cyclohexylamide (0.96 mmol) and a corresponding amount of N-methylpiperazine, 0.130 g of 36 
was obtained, 32.79 % yield, as pale orange solid, m.p. 93-94°C (toluene).1H NMR (500 MHz, 
CDCl3) δ: 1.18 (m, 2H, ax C2, cyclohexyl -CH-); 1.35 (m, 2H, ax C3, cyclohexyl -CH-); 1.37 (m, 
1H, ax C4, cyclohexyl -CH-); 1.58 (m, 1H, eq C4, cyclohexyl -CH-); 1.67 (m, 2H, eq C3, 
cyclohexyl -CH-);  1.80 (d-like signal, 4H, β-tetralinyl); 1.86 (m, 2H, eq C2, cyclohexyl -CH-); 
2.31 (s, 3H, piperazine-N-CH3); 2.50 (br, 4H, piperazine -CH2-); 2.61 (br, 4H, piperazine -CH2-); 
2.80 (d-like signal, 4H, β-tetralinoyl); 2.90 (dd, 1H, J1,2 = 4.99, J1,3 = 16.29, ABX); 3.60 (dd, 1H, 
J1,2 = 7.59, J1,3 = 16.69, ABX); 3.75 (m, 1H, cyclohexyl -CH-); 4.12 (dd, 1H, J1,2 = 5.00, J1,3 = 
7.25, ABX); 7.09 (d, 1H, J=8.67 Hz, amido -NH-); 7.12 (d, 1H, J = 9.20, aroyl-m-phenyl); 7.69 
(s, 1H, aroyl-o-phenyl); 7.70 (s, 1H, aroyl-o-phenyl); 13C NMR (125 MHz, CDCl3) δ: 22.83; 
22.96; 24.67; 25.52; 29.35; 29.58; 32.15; 32.96; 33.23; 45.85; 47.64; 55.50; 125.24; 129.07; 
129.23; 134.69; 137.28; 142.92; 170.43; 198.64. ESI-MS HR: 412.2951 (M +1), Calc. 412.2964. 
4.2.37. 2-(R,S)-(4-Benzylpiperidinyl)-4-(4-isopropylphenyl)-4-oxo-N-phenylbutanamide (37): 
        C31H36N2O2, starting from (E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid phenylamide 
(0.7 mmol) and a corresponding amount of 4-benzylpiperidine, 37 was obtained, in quantitative 
yield, as a yellow semi-solid. 1H NMR (500 MHz, CDCl3) δ: 1.26 (d, 6H, J=7.06 Hz, i-PrCH3); 
1.41 (m, 1H, piperidine -CH-); 1.72 (t-like, 4H, J=13.63 Hz, piperidine -CH2-); 2.21 (t-like, 1H, 
J=11.68 Hz, benzyl -CH2-); 2.45 (t-like, 1H, J=11.19 Hz, benzyl -CH2-); 2.56 (m, 4H, piperidine 
-CH2-); 2.94 (overlapped m, 2H, ABX and i-PrCH); 3.68 (dd, 1H, J1,2=6.81 Hz, J1,3=16.30 Hz, 
ABX); 4.29 (dd, 1H, J1,2=5.35 Hz, J1,3=6.30 Hz, ABX); 7.08 (t, 1H, J=7.50 Hz, benzyl-p-CH); 
7.13 (d, 2H, J=7.80 Hz, benzyl-m-phenyl); 7.19 (t, 1H, J=6.37 Hz, amido-p-phenyl); 7.26 (d, 2H, 
J=7.50 Hz, aroyl-m-phenyl); 7.29-7.32 (overlapped m, 4H, amido-m-phenyl and benzyl-o-
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(s, 1H, amido -NH-). 13C NMR (125 MHz, CDCl3) δ: 21.42; 23.64; 30.68; 31.93; 32.85; 33.11; 
34.21; 37.18; 37.57; 43.05; 45.12; 48.01; 52.75; 65.48; 119.29; 123.95; 12591; 126.65; 128.21; 
128.50; 128.94; 129.02; 134.90; 137.77; 140.24; 154.47; 170.47; 198.28. ESI-MS HR: 469.2852 
(M +1), Calc. 469.2855. 
4.2.38. N-(3,5-Dimethoxyphenyl)-2-(R,S)-[4-(2-dimethylaminoethyl)-1-piperazinyl]-4-(4-
isopropylphenyl)-4-oxo-butanamide (38): 
      C29H42N4O4, starting from E)-4-(4-isopropylphenyl)-4-oxo-2-butenoic acid (3,5-dimethoxy-
phenyl)amide (0.57 mmol) and a corresponding amount of 4-(2-N,N-di-Me-aminoethyl)-1-
piperazine, 38 was obtained, in quantitative yield, as a yellow semi-solid. 1H NMR (500 MHz, 
CDCl3) δ: 1.27 (d, 6H, J=7.33 Hz, i-PrCH3); 2.24 (s, 6H, N-(CH3)2); 2.43 (m, 2H, linker -CH2-); 
2.48 (m, 2H, linker -CH2-); 2.59 (br, 4H, piperazine -CH2-); 2.67 (br, 4H, piperazine -CH2-); 
2.97 (m, 1H, J1,2=6.60 Hz, J1,3=13.56 Hz, i-PrCH); 3.01 (dd, 1H, J1,2=5.13 Hz, J1,3=17.23 Hz, 
ABX); 3.68 (dd, 1H, J1,2=6.96 Hz, J1,3=17.23 Hz, ABX); 3.77 (s, 6H, -OCH3); 4.31 (dd, 1H, 
J1,2=4.77 Hz, J1,3=7.33 Hz, ABX); 6.22 (t, 1H, J=2.19 Hz, amido-p-phenyl); 6.78 (s, 2H, amido-
o-phenyl); 7.32 (d, 2H, J=8.14, aroyl-m-phenyl); 7.94 (d, 2H, J=8.46, aroyl-o-phenyl); 9.29 (s, 
1H, amido -NH-). 13C NMR (125 MHz, CDCl3) δ: 23.60; 31.85; 45.61; 54.16; 55.36; 56.47; 
56.82; 64.55; 96.36; 97.49; 126.64; 128.15; 128.45; 128.96; 134.73; 139.48; 154.59; 161.04; 
170.06; 197.72. ESI-MS HR: 511.3283 (M +1), Calc. 511.3284. 
4.3. Anticholinesterase activity assay 
The inhibition potency of the compounds 1-38 toward AChE was evaluated by Ellman 
procedure [28], using the enzyme from electric eel, type VI-S (Sigma) and acetylthiocholine 
iodide (0.28 mM) as substrate. Four to six different concentrations, which produce 20-80 % of 
enzyme activity inhibition, of the each compound were used. The reaction took place in the final 
volume of 2 mL of 0.1 M potassium phosphate buffer, pH 8.0, containing 0.03 units of AChE 
and 0.3 mM 5,5’-dithiobis(2-nitrobenzoic)acid (DTNB), used to produce yellow anion of 5-thio-
2-nitrobenzoic acid in reaction with thiocholine released by AChE. Test compound was added to 
the enzyme solution and preincubated at 25 ºC for 35 min, followed by the addition of DTNB 
(0.95 mL) and substrate (50 µL). Inhibition curves were performed at least in triplicate. One 
triplicate sample withouth test compound was always present to yield 100 % of AChE activity. 
The reaction was monitored for 3 min, and the color production was measured at 412 nm. The 
reaction rates were compared, and the percent of inhibition, due to the presence of test 
compounds, was calculated. IC50 values were determined from inhibition curves (log inhibitor 
concentration vs. percent inhibiton). 
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The investigation of butyrylcholinesterase inhibition was carried out similarly, using 0.035 
units of horse serum BChE (Sigma) and 0.5 mM butyrylthiocholine iodide, in final volume of 2 
mL.  
For determination of inhibition type for compound 17, the Lineweaver-Burk plots were 
generated by using a fixed amount of acetylcholinesterase and varying amounts of the substrate 
(0.10-0.20 mM), in the absence or presence of different inhibitor concentrations. The re-plots of 
the slopes and intercepts of the double reciprocal plots against inhibitor concentrations gave the 
inhibitor constants (Ki1 and Ki2, for the binding to free enzyme and enzyme substrate complex) 
as the intercepts on the x-axis. 
 
4.4. Molecular modeling 
 
The 3D-QSAR model for the set of the selected compounds was built using Pentacle program. 
Protonation state of the each compound was ascribed by the program under pH 8.00, the same as 
used in biological assay. Pentacle uses AMANDA [29] algorithm to produce the second 
generation of alignment-independent molecular descriptors (GRIND-2). Descriptors are obtained 
from GRID [30] molecular interaction fields (MIF's). Derived GRID MIF minima are encoded in 
the descriptors. Descriptors consist of pair of nodes, including interaction energy (IE) of each 
node and the distance between nodes. Descriptors are further processed by means of built-in 
PCA/PLS (principal component/partial least squares) statistical tool. For model generation all 
available (DRY, O, N1 and TIP) probes were used, with GRID resolution of 0.5 Å. For the 
encoding, CLAC algorithm was applied. Predictivity of the model was assessed by using leave-
one-out, leave-two-out or cross-validation usiong four groups of compounds of the 
approximately same size, in which the objects were assigned randomly, were used.  
 
Docking is a procedure for predicting the interaction and the mode of ligand binding to 
biomacromolecular targets. AutoDock 4.2 uses a semi-empirical free energy force field to 
evaluate conformations during docking calculations. The program requires pre-calculated grid 
maps, one for each atom type present in the ligand being docked. This helps to make the docking 
calculations fast. These maps are calculated by AutoGrid. A grid map consists of a three-
dimensional lattice of regularly spaced points, surrounding (either entirely or partly) and 
centered on some region of interest of the macromolecule under study. AutoDock uses one of 
several conformational search algorithms to explore the conformational states of a flexible 
ligand, using the maps generated by AutoGrid to evaluate the ligand-protein interaction at each 
point in the docking simulation. In a typical docking, the user will dock a ligand several times, to 
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conformations. Docking experiments for compounds 6, 17 and 18 were performed on the Mus 
musculus AChE structure, refined at 2.05 Å resolution (PDB entry 2HA2). Truncated residues 
were properly completed by means of Swiss PDB Viewer [31]. Hydrogen atoms were added to 
the protein aminoacid residues, non-polar hydrogens were merged, and Gesteiger charges were 
ascribed using AutoDock Tools [32]. The lowest energy conformations of the compounds were 
generated using OMEGA software [33]. Both enantiomers of the each compound were docked 
into mAChE active site gorge, using AutoDock 4.0.1 package [25] Docking was carried out by 
using hybrid Lamarckian genetic algorithm; 50 runs were performed with an initial population of 
250 randomly placed individuals and maximum number of 2.5x106 energy evaluations. Resulting 
docked poses within RMSD of 0.5 Å were clustered together. All other parameters were 
maintained at their default settings. The docking calculations were also performed using Glide 
extra precision (XP) protocol (Schroedinger) [34, 35].  Due to the fact that this procedure 
provided docking poses very similar to poses obtained by AutoDock, these results are not shown. 
Docking of compounds 16 and 20 were done following the same computational set-up as 
described for AChE, using HuBChE crystal structure (PDB entry 1P0I). 
 
 For the molecular dynamics simulations, the most populated docking pose of the (S)-
enantiomer of compound 18, retrieved by AutoDock, was used. The system was neutralized in 
VegaZZ [36] by addition of explicit sodium counterions, and afterward embedded in a cluster 
that surrounds the protein with a layer of 75 Å water molecules. For molecular dynamics 
simulations, NAMD 2.9 [37] was used, with CHARMm22 force field and Gasteiger's atomic 
charges. The system was minimized in 30,000 steps (30 ps) by conjugate gradient algorithm and, 
afterwards, heated to 300 K during 10,000 steps (10ps). The 10 ns of unconstrained, productive, 
molecular dynamics simulations was performed, at 300±10K (Langevin's algorithm), using 
periodic boundary conditions. Electrostatics was treated by a Particle Mesh Ewald algorithm. 
Cut-offs were set to 12 Å for vdW interactions, with a switch starting at 8 Å, and pair list 
distance set to 13.5 Å. Trajectory frames were collected each ps to yield 10000 frames per 
trajectory. All simulations were performed on the multi-node Linux based cluster [38] equipped 
with the dual Intel Xeon X5560 @ 2.8GHz processors. Results were analyzed in VegaZZ as 
GUI, in Windows environment. 
 
Acknowledgements: This work was supported by the Ministry of Education, Science and 
Technological Development of the Republic of Serbia, grant No 172035. The computational 
work reported makes use of results produced by the High-Performance Computing Infrastructure 
for South East Europe’s Research Communities (HP-SEE), a project co-funded by the European 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTCommission (under Contract Number 261499) through the Seventh Framework Programme HP-
SEE (http://www.hp-see.eu/). Authors gratefully acknowledge OpenEye Scientific Software, 
Santa Fe, NM, for the free academic licensing of software tools. Authors gratefully acknowledge 
computational time provided on HPCG cluster located at Institute of Information and 
Communication Technologies of the Bulgarian Academy of Science (IICT-BAS), and Prof. 
Thomas Mavromoustakos (Department of Chemistry, University of Athens) for kindly providing 
us the Glide program.  
 
Appendix. Supplementary data: Supplementary data associated with this article can be found 
in the online version, at doi: 
 
References 
 
[1] A. V. Jr. Terry, J. J. Buccafusco, The cholinergic hypothesis of age and Alzheimer’s disease - 
related cognitive deficits: Recent challenges and their implications for novel drug development,  
J. Pharm. Exp. Ther. 306 (2003) 821-827. 
 
[2] A. R. Punga, E. Stalberg, Acetylcholinesterase inhibitors in myasthenia gravis: To be or not 
to be?, Muscle and Nerve, 39 (2009) 724-728. 
 
[3] L. A. Sorbera, J. Aravamundan, C. Dulsat, Drugs of the Future, 35 (2010) 585-595. 
 
[4] G. A. Petroianiu, K. Arafat, A. Schmitt, M. Y. Hassan, Weak inhibitors protect 
cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine, J. Appl. Tox. 25 
(2005) 60-67. 
 
[5] Y. Meshulam, G. Cohen, S. Chapman, D. Alhalai, A. Levy, Prophylaxis against 
organophosphate poisoning by sustained release of scopolamine and physostigmine, J. Appl. 
Tox. 21 (2001) S75-78. 
 
[6] M. M. Mesulam, A. Guillozet, P. Show, A. Lavey, E. G. M. Duysen, O. Lockridge, 
Acetylcholinesterase knockouts establish central cholinergic pathways and can use 
butyrylcholinesterase to hydrolyze acetylcholine,  Neuroscience, 110 (2002) 627-639. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT[7] B. Li, J. A. Stribley, A. Ticu, W. Xie, L. M. Shopfer, P. Hammond, S. Brimjoin, S. H. 
Henrichs, O. Lockridge, Abundant tissue butyrylcholinesterase and its possible function in the 
acetylcholinesterase knockout mouse, J. Neurochem. 75 (2000) 1320-1331. 
 
[8] S. S. Jhee, T. Shiovitz, R. D. Hartman, J. Mesina, R. Anand, J. Sramek, N. R. Cutler, 
Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer’s disease 
who receive rivastigmine, Clin. Neuropharmacology, 25 (2002) 122-123. 
 
[9] E. K. Perry, R. H. Perry, G. Blessed, B. E. Tomlinson, Changes in brain cholinesterases in 
senile dementia of Alzheimer type, Neuropathol. Appl. Neurobiol. 4 (1978) 273-277. 
 
[10] G. Gibney, S. Camp, M. Dionne, K. MacPhee-Quigley, P. Taylor, Mutagenesis of essential 
functional residues in acetylcholinesterase, Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 7564-7550. 
 
[11] M. Ekholm, H. Konschin, Comparative model building of human butyrylcholinesterase, J. 
Mol. Struct., Teochem, 467 (1990) 161-172. 
 
[12] A. Ordentlich, D. Barak, C. Kronman, N. Ariel, Y. Segall, B. Velan, A. Shafferman, 
Functional characteristics of the oxyanion hole in human acetyl-cholinesterase, J. Biol. Chem. 
273 (1998) 19509-19517. 
 
[13] H. J. Kreienkamp, C. Weise, R. Raba, A. Aaviksaar, F. Hucko, Anionic subsites of the 
catalytic center of acetylcholinesterase from Torpedo and from cobra venom, Proc. Natl. Acad. 
Sci. U.S.A. 88 (1991) 6117-6121. 
 
[14] C. Weise, H. J. Kreienkamp, R. Raba, A. Pedak, A. Aaviksaar, F. Hucko, Anionic subsites 
of the acetylcholinesterase from Torpedo californica: affinity labeling with cationic reagent N,N-
dimetyl-2-phenyl-aziridinium, EMBO J. 9 (1990) 3885-3888. 
 
[15] J. L. Sussman, M. Harel, F. Frolow, C. Oefner, A. Goldman, L. Toker, I. Silman, Atomic 
structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding 
protein, Science 253 (1991) 872-879. 
 
[16] A. Ordentlich, D. Barak, C. Kronman, U. Flashner, M. Leitner, Y. Segall, N. Ariel, S. 
Cohen, B. Velan, A. Shaferman, Dissection of the human acetylcholinesterase active center 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTdeterminants of substrate specificity. Identification of residues constituting the anionic site, the 
hydrophobic site and the acyl pocket, J. Biol. Chem. 268 (1993) 17083-17095. 
 
[17] D. C. Velom, Z. Radić, L. Ying, N. A. Pickering, S. Camp, P. Taylor, Aminoacid residues 
controlling acetylcholinesterase and butyrylcholinesterase specificity, Biochemistry 32 (1993) 
12-17. 
 
[18] P. Taylor, S. Lappi, Interaction of fluorescence probes with acetylcholinesterase. Site and 
specificity of propidium binding, Biochemistry, 14 (1975) 1989-1997. 
 
[19] D. Barak, C. Kronman, A. Ordentlich, A. Naomi, A. Bromberg, D. Marcus, A. Lazar, B. 
Velan, A. Shafferman, Acetylcholinesterase peripheral anionic site degeneracy conferred by 
amino acid arrays shearing a common core, J. Biol. Chem. 269 (1994) 6296-6305. 
 
[20] Y. Bourne, P. Taylor, Z. Radić, P. Marchot, Structural insights into ligand interactions at the 
acetylcholinesterase peripheral anionic site, EMBO J. 22 (2003) 1-12. 
 
[21] A. Saxena, A. M. G. Redman, X. Jiang, O. Lockridge, B. P. Doctor, Differences in active 
site gorge dimensions of cholinesterase revealed by binding of inhibitors to human 
butyrylcholinesterase, Biochemistry 36 (1997) 14642-14651. 
 
[22] M. D. Vitorović-Todorović, I. O. Juranić, Lj. M. Mandić, B. J. Drakulić, 4-Aryl-4-oxo-N-
phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, 
anticholinesterase activity, docking study, and 3D structure-activity relationship based on 
molecular interaction fields, Bioorg. Med. Chem. 18 (2010) 1181-1193.  
 
[23] D. Papa, E. Schwenk, F. Villani, E. Klingsberg, β-Aroylacrylic acids, J. Am. Chem. Soc. 70 
(1948) 3356-3360. 
 
[24] P. Kulsa, D. R. Hoff, H. H. Mrozik, U. S. Pat. 4, 130, 661, Merck & Co., Inc. Rahway, N. J. 
1977. 
 
[25] G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell, A. J. 
Olson, Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity, J. 
Comp. Chem. 16 (2009) 2785-2791. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT[26] (a) G. L. Warren, C. W. ndrews, A. - . Capelli, B. Clarke, J. LaLonde, M. H. Lambert, 
M. Lindvall, N. Nevins, S. F. Semus, S. Senger, G. Tedesco, I. D. Wall, J. M. Woolven, C. E. 
Peishoff, M. S. Head, A Critical Assessment of Docking Programs and Scoring Functions, J. 
Med. Chem. 49 (2006) 5912-5931; (b) G. Schneider, Virtual screening: an endless staircase? Nat. 
Rev. Drug Discov. 9 (2010) 273-276. 
 
[27] A. C. Wallace, R. A. Laskowski, J. M. Thornton,. LIGPLOT: A program to generate 
schematic diagrams of protein-ligand interactions, Prot. Eng. 8 (1995) 127-134. 
 
[28] L. G. Ellman, K. D. Courtney, V. Jr. Andres, M. R. Featherstone, A new and rapid 
colorimetric determination of acetylcholinesterase activity, Biochem. Pharm. 2 (1961) 88-95. 
 
[29] A. Duran, G. C. Martinez, M. Pastor, Development and validation of AMANDA, a new 
algorithm for selecting highly relevant regions in Molecular Interaction Fields, J. Chem. Inf. 
Model. 48 (2008) 1813-1823; Pentacle 1.0.6, www.moldiscovery.com   
 
[30] P. J. Goodford, A computational procedure for determining energetically favorable binding 
sites on biologically important macromolecules, J. Med. Chem. 28 (1985) 849-857; GRID 22c; 
http://www.moldiscovery.com  
 
[31] N. Guex, M. C. Peitsch, SWISS-MODEL and the Swiss-PdbViewer: An environment for 
comparative protein modeling, Electrophoresis, 18 (1997) 2714-2723; 
http://www.expasy.org/spdv  
 
[32] M. F. Sanner, Python: a programming language for software integration and development. J. 
Mol. Graph. Mod. 17 (1999) 57-61. 
 
[33] a) P. C. D. Hawkins, A. G. Skillman, G. L. Warren, B. A. Ellingson and M. T. Stahl, 
Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures 
from the Protein Databank and Cambridge Structural Database, J. Chem. Inf. Model., 50 (2010) 
572-584; b) P.C.D. Hawkins, A. Nicholls, Conformer Generation with OMEGA: Learning from 
the Data Set and the Analysis of Failures, J. Chem. Inf. Model., 52 (2012) 2919-2936; OMEGA 
v. 2.4.2, OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com  
 
[34] R. A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, 
P. C. Sanschagrin, D. T. Mainz, Extra precision Glide: docking and scoring Incorporating a 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTmodel of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 49 (2006) 6177-
6196. 
 
[35] Glide, Small-Molecule Drug Discovery Suite: Schrödinger, LLC: New York, NY., 2012. 
 
[36] A. Pedretti, L. Villa, G. Vistoli, Vega - an open platform to develop chemo-bio-informatics 
applications, using plug-in architecture and script programming, J. Comput. Aided Mol. Des., 18 
(2004) 167-173; http://www.ddl.unimi.it  
 
[37] J. C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa, C. Chipot, R. D. 
Skeel, L. Kalé, K. Schulten, Scalable molecular dynamics with NAMD, J. Comput. Chem. 26 
(2005) 1781-1802; http://www.ks.uiuc.edu/Research/namd/  
 
[38] E. Atanassov, T. Gurov, A. Karaivanova, Capabilities of the HPC cluster at IICT-BAS, 
Automatika and Informatika, 2 (2011) 7-11 (in Bulgarian). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTTables: 
    Table 1. An in vitro AChE and BChE inhibition assay data for compounds 1–38 and 1a–9a.  
O
O
N
H
N
R2
R1 *
R3
 
IC50 ± SEM ( µM)a 
Comp. 
No. R1 R2  R3 AChE BChE 
1 
4-i-Pr 
3,5-di-OMe-
Ph- 
piperidine Unstableb Unstable 
2 imidazole 4.49 ± 0.18 > 20 
3 morpholine > 20 > 20 
4 N-Me-piperazine 76.65 @ 20c > 20 
5 
4-i-Pr-Ph- 
piperidine Unstable Unstable 
6 imidazole 2.33 ± 0.40 > 20 
7 morpholine > 20 > 20 
8 N-Me-piperazine > 20 72.41@ 15 
9 
Ch- 
piperidine 63.10 @ 15 64.96 @ 20  
10 imidazole 65.31 @ 15 76.01 @ 20 
11 morpholine 85.13 @ 25 46.82 @ 10 
12 N-CH3piperazine 86.24 @ 25 66.18 @ 20 
13 
2,4-di-i-Pr 
3,5-di-OMe-
Ph- 
piperidine > 7.5 > 7.5 
14 imidazole 3.30 ± 0.35 78.37 @ 20  
15 morpholine > 20 62.37 @ 10 
16 N-Me-piperazine > 20 5.26 ± 0.24 
17 
4-i-Pr-Ph- 
piperidine 1.96 ± 0.22 Insoluble 
18 imidazole 2.05 ± 0.06 > 20 
19 morpholine 44.36 @ 6.5 73.56 @ 10 
20 N-Me-piperazine 43.64 @ 6.5 0.74 ± 0.16 
21 
Ch- 
piperidine 5.44 ± 0.61 72.73 @ 20 
22 imidazole 5.94 ± 0.02 65.83 @ 20 
23 morpholine > 15 > 20 
24 N-Me-piperazine > 15 2.25 ± 0.23 
25 
β-
tetralinyl 
3,5-di-OMe-
Ph- 
piperidine 6.37 ± 1.02 > 20 
26 imidazole 3.23 ± 0.15 > 20 
27 morpholine Insoluble Insoluble 
28 N-Me-piperazine > 15 56.68 @ 20 
29 
4-i-Pr-Ph- 
piperidine Insoluble Insoluble 
30 imidazole 2.36 ± 0.20 > 20 
31 morpholine > 15 > 15  
32 N-Me-piperazine 86.48 @ 8.5 10.75 ± 1.39 
33 
Ch- 
piperidine > 20 61.46 @ 20 
34 imidazole 19.99 ± 2.00 52.23 @ 20 
35 morpholine > 15 75.22 @ 20 
36 N-Me-piperazine > 20 39.10 @ 20 
37 4-i-Pr -Ph 4-benzylpiperidine > 20 > 20 
38 4-i-Pr 3,5-di-OMe-Ph- 
4-(2-N,N-di-Me-
aminoethyl)-1-piperazine > 20 > 20 
1a 4-i-Pr -Ph piperidine 3.47 ± 0.04  7.06 ± 0.04 2a imidazole 8.22 ± 0.04 90.00 @ 30 
3a morpholine >100 72.78 @ 40 
4a 2,4-di-i-Pr -Ph piperidine 4.86 ± 0.03 60.07 @15 5a imidazole 1.55 ± 0.01 >20 
6a morpholine >10 2.48 ± 0.01 
7a 
β-
tetralinyl 
-Ph piperidine 5.64 ± 0.02 78.50 @ 15 8a imidazole 6.34 ± 0.01 83.00 @ 40 
9a morpholine >30 87.00 @ 40 
Tacrine / / / 42.95 ± 0.01 nM 6.95 ± 0.01 nM 
a
 Concentration required to produce 50% inhibition of AChE (electric eel) or BChE 
 (equine serum). IC50 values are given as the mean of three independent determinations. 
b
 Decomposition of the compounds in the enzyme inhibition assay was observed. 
c Inhibition potency of the compounds was expressed as percent of residual enzyme activity at the given concentration.  
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Table 3. Putative interactions of the selected compounds and AChE active site residues, obtained by docking calculations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Explanations: The upper part of the table corresponds to the docking poses of S enantiomers, while lower part corresponds to docking poses of R enantiomers. The assignation ‘0’ 
describes a lack of interaction between specified AChE residue and the ligand, while by ‘1’, the presence of close contacts between ligand and AChE residue is indicated. *The best 
ranked pose (E) and the most populated one (P), (E, P) – those poses are equal; ** In these columns is shown which moiety of the compounds interacts with AS (Trp 86) and PAS (Trp 
286), assignation Ph corresponds to phenylamido moiety, and Ar to aroyl moiety of the molecules. ***The type of hydrogen bond (HB) that is formed between ligand and AChE active 
site residues is indicated: HB(NH) – between -NH- amide group and –OH group of Tyr 124 side chain; HB (MeO) – between methoxy group of the ligand and –OH group of Ser 125 
side chain, or backbone -NH- group of Phe 295; HB(Im) – between imidazole nitrogen of the ligand and side chain –OH group of Ser 203, or backbone -NH-group of Phe 295; HB(CO) 
– between aroyl carbonyl group of the ligand and the  backbone -NH- group of Phe 295. 
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2 (E, P) 1 1 Ph 0 0 1 HB (NH)*** 0 0 0 1 Ar 1 1 1 HB (CO) 1 1 1 1 1 HB (MeO) -10.57 
6 (E, P) 1 1 Ph 0 0 0 HB (NH) 0 0 1 0 Ar 1 1 1 HB (CO) 1 0 1 1 1 1 -11.15 
14 (E) 1 1 Ph 1 1 1 HB (NH) 1 0 1 0 Ar 0 0 0 1 0 1 1 0 1 0 -9.67 
14 (P) 1 1 Ar 0 0 0 HB (NH) 0 0 0 0 Ph 0 1 1 HB (Im) HB (Im) 1 HB (NH) 1 1 0 -9.66 
17 (E) 0 1 Ar 1 1 1 HB (NH) 1 1 0 1 Ph 0 1 1 0 1 1 1 1 1 1 -12.65 
17 (P) 1 1 Ph 0 0 0 HB (NH) 0 0 1 0 Ar 0 0 1 1 1 1 1 1 1 1 -11.22 
18 (E) 0 0 Ar 1 1 1 HB (NH) 1 1 1 0 Ph 1 1 1 1 1 1 0 1 1 1 -9.06 
18 (P) 1 1 Ph 0 0 0 HB (NH) 0 0 1 0 Ar 0 0 1 HB (Im) 0 1 1 1 1 1 -8.96 
26 (E) 1 1 Ar 0 1 1 HB (NH) 1 0 0 HB (Im) Ph 0 1 1 HB (MeO) 1 1 0 1 1 1 -11.28 
26 (P) 1 1 Ar 0 0 0 HB (NH) 0 0 0 0 Ph 0 0 1 HB (Im) 1 1 1 1 0 HB (MeO) -10.76 
30 (E,P) 1 1 Ph 0 0 0 HB (NH) 0 0 1 0 Ar 1 1 1 HB (CO) 1 1 1 1 1 1 -11.47 
2 (E) 1 0 Ph 1 1 1 HB (NH) 1 1 0 HB (Im) Ar 0 1 1 1 1 1 1 1 1 1 -10.39 
2 (P) 1 1 Ph 0 0 0 HB (NH) 0 0 0 1 Ar 1 1 1 HB (CO) 1 1 1 1 1 1 -10.25 
6 (E, P) 1 1 Ph 0 0 0 HB (NH) 0 0 1 0 Ar 1 1 1 HB (CO) 1 0 1 1 1 1 -11.11 
14 (E) 1 1 Ph 0 0 1 HB (NH) HB (MeO) 0 0 1 Ar 0 0 1 1 0 1 1 1 1 HB (Im) -10.72 
14 (P) 1 1 Ar 0 1 1 HB (NH) 1 0 0 1 Ph 0 0 1 HB (Im) 0 1 1 1 1 1 -9.42 
17 (E) 0 1 Ar 1 1 1 HB (NH) 1 1 0 1 Ph 0 1 0 0 0 1 1 1 1 1 -10.92 
17 (P) 1 1 Ph 0 1 0 HB (NH) 0 0 1 1 Ar 0 0 1 1 1 1 1 0 0 1 -10.89 
18 (E) 0 0 Ar 1 1 1 HB (NH) 1 1 1 1 Ph 1 1 0 0 1 1 0 1 1 1 -10.62 
18 (P) 1 1 Ph 0 0 0 HB (NH) 0 0 1 0 Ar 0 0 1 HB (Im) 0 1 1 1 1 1 -10.26 
26 (N, P) 1 1 Ph 0 0 0 HB (NH) 0 0 0 1 Ar 1 1 1 1 1 1 1 1 1 HB (Im) -11.00 
30 (E) 1 1 Ar 0 1 1 HB (NH) 1 0 0 HB (Im) Ph 0 1 1 1 1 1 0 1 1 HB (Im) -11.62 
30 (P) 1 1 Ar 0 1 0 HB (NH) 0 0 0 0 Ph 0 1 1 HB (Im) 0 0 1 1 0 1 -10.78 
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Component SSX SSXacc SDEC SDEP R2 R2acc Q2acc LOO Q2acc LTO Q2acc RG 
1 24.16 24.16 0.25 0.32 0.63 0.63 0.40 0.41 0.41 
2 14.99 39.16 0.14 0.23 0.25 0.88 0.68 0.67 0.65 
3 6.93 46.09 0.09 0.20 0.07 0.96 0.76 0.74 0.72 
4 11.46 57.55 0.07 0.20 0.02 0.97 0.76 0.75 0.73 
5 4.55 62.10 0.04 0.20 0.02 0.99 0.77 0.76 0.73 
Abbreviations: SSX, X variable explanation; SDEC, standard deviation of error of calculation; SDEP standard 
deviation of error of prediction; The ‘acc’ states for cumulative value; Validation methods used for calculation of q2 
are: leave one out (LOO), leave two out (LTO) and random groups (RG). Four random groups were used. 
 
Figure captions: 
 
Scheme 1. Synthetic path to 1-38. Reagents: (a) AlCl3/CH2Cl2; (b) POCl3, dry THF. R2 = 3,5-
dimetoxyaniline, 4-isopropylaniline, or cyclohexylamine; (c) toluene, CH2Cl2 and R3 = 
piperidine, imidazole, morpholine, N-methylpiperazine, 4-benzylpiperidine and 4-(2-N,N-di-Me-
aminoethyl)-1-piperazine. 
 
Figure 1. Lineweaver-Burk plot of AChE (0.02 U) with substrate acetylthiocholine, in the 
absence and in presence of different concentrations of 17. (■) No inhibitor; (●) 2 µM;(▲) 4 
µM;(▼) 5 µM. 
 
Figure 2. PLS coefficients plot, obtained with 3LV. 
 
Figure 3. Compounds 6, 17 and 18 docked into the AChE active site. The S enantiomers are 
colored cyan and R enantiomers are colored red. (a) best ranked pose for 17; (b) best ranked pose 
for 18; (c) the most populated pose for 17; (d) most populated pose for 18; (e) best ranked /most 
populated pose for 6. 
 
Figure 4. The most important distances between AChE residues and compound 18 moieties, 
derived from the 10 ns of unconstrained MD: (a) Distance between centroids of phenylamide 
ring of 18 and Trp 82 aromatic side chain; (b) Blue squares-distance between centroids of aroyl 
ring and Trp 286 indole ring; violet dots – distance between centroid of Trp 286 indole ring and 
Me-group of ortho-i-Pr moiety; (c) Hydrogen bond between N3 of imidazole ring and: green 
dots - backbone -NH- group main chain nitrogen atom of Phe 295; red dots - -OH group oxygen 
of Tyr 124   (d) Distance between side chain -OH group oxygen of Tyr 124 and nitrogen atom of 
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ACCEPTED MANUSCRIPTamido -NH- group; (e) distance between oxygen atom of Tyr 72 –OH group and carbonyl group 
of compound 18. 
 
Figure 5. Compounds 16 (left) and 20 (right) docked into the BChE active site. The S 
enantiomers are colored cyan and R enantiomers are colored red.  
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Figure 2. PLS coefficients plot, obtained with 3LV. 
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Figure 3. Compounds 6, 17 and 18 docked into the AChE active site. The S enantiomers are 
colored cyan and R enantiomers are colored red. (a) best ranked pose for 17; (b) best ranked pose 
for 18; (c) the most populated pose for 17; (d) most populated pose for 18; (e) best ranked /most 
populated pose for 6. 
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Figure 4. The most important distances between AChE residues and compound 18 moieties, 
derived from the 10 ns of unconstrained MD: (a) Distance between centroids of phenylamide 
ring of 18 and Trp 82 aromatic side chain; (b) Blue squares-distance between centroids of aroyl 
ring and Trp 286 indole ring; violet dots – distance between centroid of Trp 286 indole ring and 
Me-group of ortho-i-Pr moiety; (c) Hydrogen bond between N3 of imidazole ring and: green 
dots - backbone -NH- group main chain nitrogen atom of Phe 295; red dots - -OH group oxygen 
of Tyr 124   (d) Distance between side chain -OH group oxygen of Tyr 124 and nitrogen atom of 
amido -NH- group; (e) distance between oxygen atom of Tyr 72 –OH group and carbonyl group 
of compound 18. 
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Figure 5. Compounds 16 (left) and 20 (right) docked into the BChE active site. The S 
enantiomers are colored cyan and R enantiomers are colored red.  
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Highlights: 
 
► 4-Aryl-4-oxo-2-aminylbutanamides were evaluated for anticholinesterase activity. 
►Twelve compounds exerted low micromolar inhibition potency toward AChE. 
►Three compounds inhibited BChE in low micromolar or submicromolar concentrations. 
► A hydrogen bond can be formed between compounds -NH- group and AChE Tyr 124 –
OH. 
► The selectivity of compounds is governed by the nature of cycloalkylamino moiety.  
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Structural modifications of 4-aryl-4-oxo-2-aminylbutyramides and their acetyl- and 
butyrylcholinesterase inhibitory activity. Investigation of AChE-ligand interactions by 
docking calculations and molecular dynamics simulations. 
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Table S1. Data of enzymatic analysis (Ki) for the compound 17. 
 
 
1/[S] x 103 
(mol-1) 
V-1 (min/∆A) for [I] (µM) 
0,00 2,00 4,00 5,00 
5.05 3.571 5.102 8.064 13.888 
5.618 3.676 5.555 8.333 15.625 
6.329 3.789 5.814 8.621 16.666 
7.246 4.111 6.25 9.615 17.857 
8.928 4.386 6.579 10.417 19.23 
 
 
Table S2. Predicted potency of the compounds based on model described in reference 22, given 
in the main text. 
Compound No Exp. p(IC50)* Calc. p(IC50) 
2 5.348 5.478 
6 5.633 5.634 
14 5.481 5.433 
17 5.708 5.555 
18 5.688 5.503 
21 5.264 5.088 
22 5.226 5.329 
25 5.196 5.197 
26 5.491 5.544 
30 5.627 5.759 
34 4.699 5.224 
                * Recalculated from M concentrations.  
 
 
                                                 
*
 Corresponding author: mvitod@chem.bg.ac.rs  
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a) b) 
Figure S3.  Heatmaps of: a) DRY-DRY block of variables; b) N1-N1 block of variables. 
Compounds were arranged from the most to the least active one, from the top to the bottom of the 
Figure. 
 
 
 
Figure S4. Variable O-TIP 473 (10.0-10.4 Å), on the example of the most active derivative 18. 
 
Table S5. Experimental vs. calculated p(IC50) values obtained with 3LV from PLS model described in 
the main text. In the last column, association of variable O-TIP 473 with compounds is shown. 
Compound No Exp. p(IC50) Calc. p(IC50) O-TIP 473 Variable* 
1a 5.460 5.203 – 
2a 5.085 5.031 + 
4a 5.313 5.372 + 
5a 5.810 5.716 + 
7a 5.249 5.365 + 
8a 5.198 5.199 + 
2 5.348 5.451 + 
4 4.553 4.589 + 
6 5.633 5.561 + 
9 4.638 4.657 – 
10 4.602 4.646 – 
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11 4.398 4.401 – 
12 4.398 4.400 – 
14 5.482 5.506 + 
17 5.708 5.794 + 
18 5.688 5.660 + 
19 5.131 5.302 + 
20 5.143 5.218 + 
21 5.264 5.185 + 
22 5.226 5.126 + 
25 5.196 5.204 + 
26 5.491 5.401 + 
30 5.627 5.619 + 
32 4.921 5.019 + 
34 4.699 4.634 – 
       * (+) - Variable has a value different from 0. (–) - Variable has a value 0.  
 
Table S6. Statistics of PCA model 
Component SSX SSXacc VarX VarXacc 
1 24.47 24.47 21.04 21.04 
2 16.33 40.8 14.15 35.19 
3 9.80 50.60 8.05 43.24 
4 7.75 58.35 6.42 49.66 
5 5.33 63.68 4.05 53.71 
Abbreviations: SSX – percentage of the X sum of the 
squares; VarX – percentage of the X variance. The ‘acc’ states 
cumulative value. 
 
 
Table S7. RMSD of the atomic positions between docked poses of R and S enantiomers, for the 
energetically best ranked (E), and the most populated (P) pose of compounds 6, 17 and 18. 
Compound 
No 
RMSD (Å) 
H atoms 
included heavy atoms only 
6 (E, P) 1.811 1.810 
17 (E) 2.350 1.480 
17 (P) 2.077 2.077 
18 (E) 1.874 1.220 
18 (P) 2.312 1.440 
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a) 1H NMR spectrum of compound 4 
 
b) 13C NMR spectrum of compound 4 
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c) 1H NMR spectrum of compound 6 
 
d) 13C NMR spectrum of compound 6 
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e) 1H NMR spectrum of compound 16 
 
 
f) 13C NMR spectrum of compound 16 
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g) 1H NMR spectrum of compound 24 
 
 
h) 13C NMR spectrum of compound 24 
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i) 1H NMR spectrum of compound 26 
 
 j) 13C NMR spectrum of compound 26 
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k) 1H NMR spectrum of compound 31 
 
 
l) 13C NMR spectrum of compound 31 
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Figure S7. NMR spectra of representative compounds. 
